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ABSTRACT 
 
HIV infection poses a major obstacle in breastfeeding as it represents the most common way 
by which children acquire HIV.  Exclusive breastfeeding has been discovered as the most 
effective intervention in preventing mother-to-child transmission of HIV, mortality and 
promotion of HIV free survival.   
The main objective was to evaluate the evidence on the effectiveness of exclusive 
breastfeeding versus formula feeding and/ or mixed feeding in the prevention of HIV-1 
transmission from mother to child.   
To identify the studies, an electronic search was conducted using PUBMED/MEDLINE, 
CINAHL, CENTRAL and EMBASE databases. Electronic journals, which include the 
Southern African Journal of HIV medicine (SAJHIV), HIV Medicine Journal and American 
Journal of Public Health, were also accessed.  Manual searches were carried out.  In 
addition, relevant experts were contacted in order to locate more data.  There were no 
limitations with regards to date and language.   
The review considered studies on infants who were vertically HIV-1 exposed (mother HIV 
positive during pregnancy, birth and breastfeeding).  These infants were exclusively 
breastfed for six months with administration of antiretroviral prophylaxis and were compared 
to infants exclusively formula fed.  The outcomes measured were vertically acquired HIV 
infection; mortality and HIV free survival up to 24 months of age.   
Two reviewers independently selected articles which met the inclusion criteria.  They 
independently extracted the data using a data extraction tool.  Disagreements were solved 
by discussion.  Data was then meta-analysed using Rev Man 5.1.0.   
 
Methodological quality of each trial was assessed by the reviewers using the Cochrane 
assessment tool for risk of bias. 
Two randomised clinical trials and one intervention cohort study (n=2112 infants) comparing 
exclusive breastfeeding with exclusive formula feeding were included.  HIV infection was 
associated with exclusive breastfeeding as compared with exclusive formula feeding (Risk 
ratio 1.67, 95% CI 1.26 to 2.23, p=0.0005).  Exclusive formula feeding was associated with 
high mortality from infections (Risk ratio of 0.67 95% CI 0.43 to 0.83, p=0.002 Chi²= 1.30, 
p=0.52, I²=0%).  There were no statistically significant differences in HIV free survival 
between exclusive breastfeeding and exclusive formula feeding as measured by trialists at 9, 
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18 and 24 months (Risk ratio 1.19, 95% CI, 0.92 to 1.54, p=0.19, Chi²= 3.15, p=0.21, I²=36 
% 3 studies, 1012 infants).  None of the studies included reported on mixed feeding.   
Complete avoidance of breastfeeding is effective in preventing mother-to-child transmission 
of HIV.  HIV infection during breastfeeding might be an indicator of mixed feeding and poor 
adherence.  Formula feeding is only applicable in settings where formula milk is accessible, 
feasible, acceptable, safe and sustainable (AFASS) because formula feeding carries a high 
risk of mortality from causes other than HIV.  If the AFASS criteria cannot be met, mothers 
should be encouraged to exclusively breastfeed and ensure that their infants completely 
adhere to the antiretroviral prophylaxis because they decrease the rate of vertical HIV-1 
transmission.   
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OPSOMMING 
 
MIV besmetting veroorsaak ‘n groot struikelblok vir borsvoeding, omdat dit die mees 
algemene manier is waarop babas met MIV besmet  word.  Eklusiewe borsvoeding is as die 
mees effektiewe intervensie ontdek in die voorkoming van moeder na kind oordrag van MIV, 
morbiditeit en die bevordering van MIV vrye oorlewing.   
Die hoofdoelwit is om die effektiwiteit van eksklusiewe borsvoeding teenoor formule-voeding 
en of gemengde voeding in die voorkoming van MIV oordrag van moeder na kind te 
evalueer.   
Elektroniese navorsing is gedoen deur gebruik te maak van PUBMED/MEDLINE, CINAHL, 
CENTRAL en EMBASE databasisse.  Elektroniese joernale wat die Southern African Journal 
of HIV medicine (SAJHIV), HIV Medicine Journal and American Journal of Public Health 
insluit, is ook gebruik.  Handnavorsing is ook gedoen, asook relevante data van kenners op 
die gebied, is verkry.  Geen beperking is geplaas op taal of tyd nie.   
Studies op babas wat blootgestel is aan die MIV-1 (moeder MIV positief gedurende 
swangerskap en borsvoeding) is in die oorsig oorweeg.  Hierdie babas is eksklusief vir 6 
maande gerborsvoed, met of sonder anti-retrovirale behandeling, en is vergelyk met 
eksklusiewe formule-voeding.  Die resultaat was dat almal tot op 24 maande gemeet is aan 
MIV besmetting, mortaliteit en MIV vrye oorlewing.   
Twee resensente het onafhanklik artikels geselekteer wat aan die ingeslote kriteria voldoen 
het.  Hulle het onafhanklik data geselekteer deur van ’n selekteringsinstrument gebruik te 
maak.  Misverstande is deur besprekings opgelos.  Data was daarna gemeet en gemeta-
analiseer deur Rev Man 5.1.0.   
Die metadologiese kwaliteit van elk proeflopie is geassesseer deur die resensente wat 
gebruik gemaak het van die Cochrane evalueringsinstrument om die risiko van 
onewewigtigheid uit te skakel.   
Twee ewekansige kliniese proewe en een intervensie kohort studie (n = 2112 babas) wat 
eksklusiewe borsvoeding vergelyk met 'n eksklusiewe formule-voeding is ingesluit. MIV-
infeksie wat verband hou met 'n eksklusiewe borsvoeding is vergelyk met eksklusiewe 
formule-voeding (risiko verhouding van 1.67, 95% CI 1.26 tot 2,23, p=0.0005).  Eksklusiewe 
formule-voeding hou verband met 'n hoë mortaliteit van infeksies met ’n risiko verhouding 
van 0.67, 95% CI 0.43 tot 0.83, p = 0.52, Chi ² = 1.30, p = 0.52, I ² = 0%.  Daar is geen 
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statisties beduidende verskille in MIV-vrye oorlewing tussen eksklusiewe borsvoeding en 
eksklusiewe formule-voeding nie wat deur die proefnemers gemeet is op 9, 18 en 24 
maande (risiko verhouding 1.19, 95% CI, 0.92 tot 1.54, p = 0,19, Chi ² = 3,15, p = 0.21, I ² = 
36% 3 studies, 1012 babas).  Nie een van die ingeslote studies het verslag gedoen oor  
gemengde voeding nie. 
Algehele vermyding van borsvoeding is effektief in die voorkoming van Moeder na Kind 
oordrag van MIV.  MIV-infeksie gedurende borsvoeding mag ’n aanduiding van gemengde 
voeding en swak nakoming wees. Formule voeding is alleenlik van toepassing in situasies 
waar formule-melk toeganklik, uitvoerbaar, veilig en volhoubaar is, want formule-voeding dra 
’n hoë risiko van mortaliteit weens ander oorsake buiten MIV. Indien daar nie aan hierdie 
kriteria voldoen kan word nie, behoort moeders aangemoedig te word om eksklusief te 
borsvoed en seker te maak dat hulle babas die antiretrovirale profilaksie getrou neem, want 
dit verlaag die koers van vertikale MIV-1 oordrag. 
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CHAPTER 1 
SCIENTIFIC FOUNDATION OF THE STUDY 
 
1.1 INTRODUCTION 
BACKGROUND: DESCRIPTION OF THE CONDITION AND INTERVENTION 
Human immune-deficiency virus (HIV), the causative virus of Aquired Immune Deficiency 
Syndrome (AIDS), is transmitted in various ways to an infant.  Vertical or mother-to-child 
transmission of HIV can occur transplacentally in utero, at the time of delivery or through 
breastfeeding (Cronje & Grobbler, 2003:428).  According to Nolte (2007:359), a woman may 
acquire HIV during sexual intercourse with an infected partner, through sharing of infected 
objects or during blood transfusion with HIV infected blood.  
During the past decades, breastfeeding has been encouraged to improve both maternal and 
child health.  Holmes and Salvage (2007:1065) indicated immediate and long term benefits 
of breastfeeding, which is a cost effective intervention for child survival which could prevent 
13-15% of child deaths in low income countries.  Breastfeeding protects against common 
infections such as diarrhoea, pneumonia, neonatal sepsis and otitis media (Newell, 2004:5).  
A study conducted in Brazil found that infants who were not breastfed were 17 times at 
higher risk of hospital admission (OR 16.7, 95% CI 7.7-36) (Newell, 2004:5).  According to 
Horvath, Madi, Kennedy, Rutherford and Read (2010:4), the epidermal growth factor in the 
colostrum helps to make the gastrointestinal tract less permeable to viral infection. 
Without any specific interventions, HIV transmission via breastfeeding accounts for an 
estimated 24-44% of infant infections (Lehman, Chung, John-Stewart, Kinuthia & Overaugh, 
2008:2).  According to Holmes and Salvage (2007:1065), the joint United Nations 
Programme on HIV/AIDS (UNAIDS) estimates that over 300 000 children are infected with 
HIV through breastfeeding every year.  Despite the conflicting issue of breastfeeding being a 
risk factor for HIV infection in HIV-1 exposed infants and breastfeeding being important in 
the promotion of growth and protection against common infections, exclusive breastfeeding 
will reduce the chances of HIV transmission as opposed to mixed feeding. (Newell, 2004:5).  
Exclusive breastfeeding implies that an infant receives only breast milk, and no other liquids 
or solids, not even water, with the exception of drops or syrups consisting of vitamins, 
mineral supplements or medicines (Newell, 2004:1). 
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 Mixed feeding disturbs the lining or causes trauma to the gastrointestinal tract of the infant, 
hence the risk of mother-to-child transmission of HIV is higher (Fraser, Cooper & Nolte, 
2006:366).  According to the Department of Health in the Republic of South Africa 
(2008:115), mixed feeding carries the highest risk of HIV transmission and should be 
discouraged.   
Replacement feeding with formula feeding carries a higher infant mortality risk (Thior, 
Shapiro, Smeaton, Lockman, Rossenkhan, et al., 2009:1).  To make breastfeeding safe, 
breast milk pasteurization, a hot water bath and microbicidal treatment with alkyl sulphates 
have been proposed (Thior et al., 2006:794).   
Currently, HIV exposed infants are given doses of antiretroviral medication.  Such 
prophylaxis is designed to protect the uninfected infant while exposed to the HI-virus through 
breastfeeding.  Prophylactic antiretroviral regimes are taken during pregnancy, intrapartum 
and postnatally by the mother, as well as by the infant postpartum.  In places of adequate 
infrastructure, the World Health Organisation currently recommends a combination of these 
regimens (lamuvidine, zidovudine and nevirapine) (WHO, 2009: 9).  In developing countries 
a single daily dose of nevirapine remains to be widely used and has been proven to reduce 
HIV transmission via breast milk during the early postpartum period when the majority of 
breast milk transmission occurs (Lehman et al., 2008:2).   
Several studies have been conducted to prove the effectiveness of exclusive breastfeeding 
in HIV exposed infants.  In Botswana, Thior et al., (2006:1-13), compared exclusive 
breastfeeding plus infant zidovudine prophylaxis for 6 months with formula feeding, plus 
infant zidovudine for one month.  The results of this randomised controlled study reported 
comparable rates of HIV-free survival at 18 months in both interventions.  Formula feeding 
had a higher risk of high morbidity and mortality rates but breastfeeding with zidovudine 
prophylaxis had a higher risk of HIV transmission at 7 months.  In a study carried out in 
Kwazulu-Natal in South Africa, exclusively breastfed infants carried a significantly lower risk 
of transmission of HIV than all types of mixed feeding.  Those who received breastmilk and 
solids were eleven times at risk of becoming HIV infected, while those on breastmilk and 
formula feeds were twice at risk (Coovadia, Rolling, Bland, Little, Coutsoundis et al., 
2007:1112 ).   
 
In a systematic review conducted by Horvath et al., (2010:17), six randomised clinical trials 
and one intervention cohort study were included and they concluded that complete 
avoidance of breastfeeding is efficacious in preventing mother-to-child transmission of HIV.  
Stellenbosch University http://scholar.sun.ac.za
  3
Furthermore, if breastfeeding is initiated, the two interventions that are efficacious in 
preventing transmission are exclusive breastfeeding and extended antiretroviral prophylaxis.   
 
1.2 PROBLEM STATEMENT 
The effectiveness of exclusive breastfeeding among HIV exposed infants is still unclear.  
There are numerous controversial and ethical issues surrounding this intervention.  Through 
postnatal experience, some health care professionals do not approve of exclusive 
breastfeeding in HIV cases due to reported high transmission rates; as a result they fail to 
reinforce exclusive breastfeeding when it is applicable.  Mothers are exposed to the HIV 
stigma if they do not breastfeed, as there is an assumption that the mother is HIV positive, 
while in other cases women suffer the abuse of family members, especially from male family 
members.  Most women lack information on the effectiveness of exclusive breastfeeding in 
HIV exposed infants.   
 
1.3 HOW EXCLUSIVE BREASTFEEDING MIGHT WORK 
Exclusive breastfeeding is considered the best feeding option in poorly resourced 
communities where formula feeding is not feasible, unacceptable, unsafe, not sustainable 
and unaffordable.  An extensive literature search has shown that exclusive breastfeeding 
reduces other significant risks, such as increased diarrhoea and pneumonia morbidity and 
mortality (Thior et al., 2006:1-13: Newell 2004:5).   
 
Exclusive breastfeeding with antiretroviral prophylaxis is associated with less than 5% HIV 
transmission.  In the MITRA Plus trial from Tanzania, ART and breastfeeding was 
associated with a cumulative transmission at six months of only 5.0% (less than 1% had 
been infected during the period of breastfeeding) (Kilewo, Karlsson, Ngarina, Massawe, 
Lyamuya et al., 2008:1).  The AMATA study in Rwanda, found that only one out of 174 
(0.6%) breastfeeding women on maternal Highly Active Antiretroviral Therapy transmitted 
HIV to her infant (Peltier, Ndayisaba, Lepage, Griensven, Leroy et al., 2009:2415).   
 
Coovadia et al., (2007:1107) conducted a study in Durban, South Africa and found that 
mixed feeding was associated with an increased HIV transmission rate, while exclusive 
breastfeeding had a lower transmission rate.  This influenced the revision of the present 
UNICEF, WHO and UNAIDS infant feeding guidelines.  Exclusive formula feeding has a 0% 
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HIV transmission rate but the rate of mortality from causes other than HIV is higher (Peltier 
et al., 2009:2415).   
Despite HIV infection via breastfeeding in HIV exposed infants, breastmilk has been proved 
to be a cost effective intervention and is associated with good maternal and child health.   
 
1.4 SIGNIFICANCE OF THE REVIEW  
Individual study results can often not be generalised. By combining outcomes of various 
trials, this systemic review can yield reliable and evidence based results.  The primary aim of 
this systematic review was to critically appraise and review the evidence based on the 
effectiveness of exclusive breastfeeding in the prevention of HIV transmission from mother 
to child as compared to exclusive formula feeding.  Across the studies, the efficacy of 
exclusive breastfeeding has been determined through comparison with exclusive formula 
feeding and mixed feeding.  The secondary aim was to summarise evidence on mortality 
and HIV free survival in HIV exposed breastfed infants.  Therefore, results of this systematic 
review can inform practice and awareness can be raised regarding effective feeding options 
in HIV exposed infants in both, the community and amongst patients.   
 
1.6 AIM 
Before the commencement of the study, the following review question was posed: Is 
exclusive breastfeeding (with the use of antiretroviral therapy) effective in the prevention of 
mother-to-child transmission of HIV-1 infection as compared to exclusive formula feeding 
and/or mixed feeding.  Therefore, the aim of the systematic review was to compare the 
effectiveness of exclusive breastfeeding versus that of formula feeding and/ or mixed feeding 
with the use of antiretroviral prophylaxis in the prevention of HIV-1 transmission from mother 
to child.   
 
1.7 OBJECTIVES 
Primary objective 
1. To evaluate the evidence on exclusive breastfeeding in the prevention of mother-to-child 
transmission of HIV-1 infection as compared to exclusive formula feeding and/ or mixed 
feeding with the use of antiretroviral prophylaxis.   
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Secondary objectives 
1. To compare the mortality rates in exclusive breast-fed infants as compared to exclusively 
formula and/ or mixed-fed infants as measured up to 24 months.   
2. To determine the HIV-free survival as measured up to 24 months in exclusive breast-fed 
infants as compared to exclusively formula and/ or mixed-fed infants. 
1.8 HYPOTHESIS 
It was hypothesised that exclusive breastfeeding with the use of antiretroviral prophylaxis is 
more effective than formula feeding (in instances where formula feeding is NOT acceptable, 
affordable, feasible, sustainable and safe) and/ or mixed feeding in the prevention of HIV-1 
transmission from mother to child.  
 
1.9 RESEARCH METHODOLOGY 
1.9.1 Introduction 
Rothstein, Sutton and Borenstein (2005:351), define a systematic review as a review of a 
clearly formulated question that involves systematically finding, critically appraising and 
combining evidence from scientific trials and aims at minimising bias and synthesizing 
evidence based results.  According to Higgins and Green (2006:98-99), a small effect can be 
detected through systematic reviews; individual studies may not have significant outcomes, 
therefore, combining two or more homogenous studies through meta-analysis results in 
improved detection of treatment effects.   
 
1.9.2 Criteria for considering studies for this review 
1.9.2.1 Types of studies 
Studies included in this systematic review were randomised controlled clinical trials (RCTs) 
and a cohort study.  RCTs have an eligible and important study design which is important 
when dealing with questions on therapeutic effectiveness (Higgins & Green, 2006:60).   
 
1.9.2.1a Types of participants 
Studies on infants who were HIV-1 exposed (mother HIV positive during pregnancy) and 
were either exclusively breastfed or exclusively formula fed were considered in the review.   
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1.9.2.1b Types of interventions and comparisons 
According to Glasziou (2001:121), an intervention will generally be a therapeutic procedure 
such as a treatment with a pharmaceutical agent or dietary requirements.  In this review, 
experimental interventions from selected studies were to include exclusive breastfeeding (six 
months duration) compared to formula feeding and/ or mixed feeding under an antiretroviral 
prophylaxis.   
According to Coutsoudis, Pillay, Kuhn, Spooner, Tsai and Coovadia (2001:472), outside the 
context of HIV, exclusive breastfeeding from 0-6 months is the single most effective strategy 
to reduce infant mortality worldwide.  Furthermore, in cases of HIV exposed infants, there is 
1% chance per month of HIV transmission through breastfeeding without antiretroviral 
prophylaxis: the longer the duration of breastfeeding, the higher the risk of HIV transmission 
(Leroy, 2007:9).   
 
1.9.2.1c Type of outcome measures 
It is vital for authors to state the outcome measures clearly and in a meaningful manner.  
They should be of importance to the policy makers as well as health care professionals so 
that they can give results based on care which is crucial to patient care (Higgins & Green 
2006:60).  In this systematic review, the outcome measures of interest are as follows: 
Primary outcomes 
1. HIV infection as measured up to 24 months   
Secondary outcomes 
1. Infant mortality measured up to 24 months   
2. HIV-free survival as measured up to 24 months   
 
1.9.3 Exclusion criteria 
As stated in the protocol, studies showing an attrition rate of more than 15% were to be 
excluded.  Due to longer duration of studies and a possibility of high attrition rate, a minimum 
of 20% loss to follow up was considered.  Studies not reporting outcomes of interest were 
excluded.   
Stellenbosch University http://scholar.sun.ac.za
  7
There are different reasons why study participants may be lost or withdraw from a study.  
This could be due to side effects of the study drug, loss of interest by participants, death, 
change of address or loss during follow-up (Higgins et al., 2006:203).  Table 4.5 in chapter 4 
shows some detailed reasons why most studies were excluded from the review.   
 
1.10 SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES 
1.10.1 Electronic search strategy 
Databases of health related documents (or similar) including PUBMED/MEDLINE (Medical 
Literature Analysis and Retrieval System Online), EMBASE, (Excerpta Medica Database), 
CINAHL (Cumulative Index of Nursing and Allied Health Literature), Cochrane Clinical Trial 
Register and Cochrane HIV/AIDS Group/CENTRAL (Cochrane Central Register of 
Controlled Trials) were searched extensively.  A search of electronic journals was done.  
Breastfeeding and HIV textbooks, as well as HIV/AIDS conference proceedings were also 
accessed.  There were no limitations to language or date during the search and the articles 
were peer reviewed publications.  Both published and unpublished data were accessed.  
The medical search headings (MeSH terms) that were used for searching data included: 
exclusive breastfeeding, HIV, infant feeding, interventions, prevent HIV transmission, 
postnatal HIV transmission, randomised, randomized, randomisation and randomization.  A 
general search strategy was adapted for each database.   
 
1.10.2 Other sources 
Links from electronic data or reference lists were referred to in order to source more studies.  
Glasziou (2001:1) states that this process is referred to as ‘snowballing’ and reviewers 
broaden their search using these methods; therefore, important studies are rarely missed.  
To obtain more data, study trialists, experts such as breastfeeding specialists, midwives, HIV 
counsellors, HIV conference proceedings and breastfeeding organisations were consulted.   
1.11 DATA EXTRACTION AND ANALYSIS 
1.11.1 Selection of studies 
The strategy of critical appraisal and selection was adopted to identify the studies meeting 
the inclusion criteria.  The primary reviewer, Angel Phuti (AP) assessed the titles of all the 
studies obtained during an extensive literature search.  AP and OK (Oswell Khondowe) 
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independently screened and eliminated the irrelevant ones.  The abstracts of those 
remaining were also assessed to determine if they were eligible.  Abstracts were read by 
both reviewers to assess for eligibility.  Full articles of eligible studies were read and relevant 
information was extracted.  Any discrepancies were resolved through discussions and Kim 
Harper (KH) was available for further consultations.  A data extraction form was used to 
collect and extract information from the studies.   
 
1.11.2 Assessment of methodological quality 
To ensure data validity and reliability, the researchers (AP) and (OK), independently 
assessed the data quality using the Cochrane assessment tool.  For any further 
consultations, a third reviewer (KH) was available.   
Every included study was judged using six domains as follows: sequence generation, 
allocation concealment, blinding of participants, as well as personnel and outcome 
assessors, incomplete outcome data assessment outcome reporting and other sources of 
bias.  Each question or domain was rated as either high risk, low risk or unclear.  A 
judgement of each domain was then entered into Rev Man 5.1.0 and a risk of the bias table 
was obtained.   
 
1.11.3 Data extraction and management 
A standardised data extraction tool form was used to extract and collect the information 
relevant for this review.  The reviewers independently extracted the data from the articles.  
Notes were then compared.  Where there was a variance, the two reviewers discussed the 
variance and came to an agreement.   
 
1.11.4 Measurement of treatment effect 
The measure of effect that was to be used was the relative risk (RR) for dichotomous data 
with a 95% confidence interval (CI) and a p-value of 0.05 using the random effects model to 
accommodate potential bias.  Relative risk is defined as the chance of developing a disease 
condition relative to exposure (Deeks, Higgins & Altman 2006:103).  The meta-analysis 
method is available in the software Rev Man 5.1.0 for analyses (Deeks et al., 2006:101-136).  
A calculation of relative risk or RR and OR is as follows: 
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Table 1.1: Calculation of relative risk or odds ratio 
 Event No event Total 
Intervention A B a + b 
Control C D c + d 
 
RR = risk of event in the intervention group [a/ (a+b)] ÷ risk of event in control group [c/ (c + 
d)] (Higgins et al., 2006: 102).   
 
1.11.5 Dealing with missing data   
Authors were to be contacted for missing data, as well as including articles which used the 
intention to treat analysis.   
 
1.11.6 Assessment of heterogeneity 
A statistical test strategy, the chi-squared test, I-squared test and forest plot, were used to 
measure or assess whether observed differences in results are compatible with chance 
alone (Higgins and Green, 2006:137-138).  A more detailed summary on how the reviewers 
assessed heterogeneity is presented in Chapter 3. 
 
1.11.7 Data synthesis (meta-analysis) 
Rev Man 5.1.0 was used for meta-analysis.  The measure of effect of choice was the relative 
risk (RR) with a 95% confidence interval (CI) for dichotomous data and a p-value of 0.05.  
The random effects model was incorporated to accommodate heterogeneity that could not 
be explained thus eliminating potential bias.  To demonstrate and illustrate the effects of 
interventions, forest plots were used.   
 
1.11.8 Subgroup analysis and sensitivity analysis 
Due to clinical diversity across the studies, subgroup analysis was done.  Measurements of 
the outcomes; HIV infection, HIV free survival and infant mortality were done at different 
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ages and there could be unknown inconsistencies.  Sensitivity analysis was incorporated 
during meta-analysis to determine if the same results could be obtained.   
 
1.12 ETHICAL CONSIDERATIONS 
Permission to conduct this study was sought from the Ethics Committee at Stellenbosch 
University.  A panel of research methodology experts in the Division of Nursing reviewed the 
protocol and permission for the study to proceed was given by the Ethics Committee.  The 
registration number assigned to the protocol was N10/11/391.  All trials used in the review 
were registered by their relevant Ethics Committee.   
 
1.13 DISSEMINATION OF RESULTS 
A report in thesis form was submitted as part of the fulfilment of a Master’s of Nursing 
(MCur) degree to Stellenbosch University.  The researcher will present the results at a 
relevant conference and will publish in an accredited journal.  Reader friendly copies will be 
distributed to a variety of educational places and health institutions.  These will include 
universities, community health centres, policy makers and community libraries or 
newspapers.   
 
1.14 STUDY LAYOUT 
Chapter 1: Introduction: Scientific foundation of the study 
The chapter focuses on the overview of the research field, background, rationale and 
preface of research methods.   
Chapter 2: Literature review 
This chapter contains information on what is currently known or documented about the 
research topic.   
Chapter 3: Research methodology 
It elaborates in detail on the methodology used to conduct the systematic review, as well as 
the study design.   
Chapter 4: Results, Data synthesis, Results interpretation and presentation 
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The chapter shows how the data is managed and presented in tables and graphs.  The 
reviewer discusses the results in relevance to the hypothesis and research question.   
Chapter 5: Conclusion/recommendations 
A summary of the systematic review main findings is documented in this chapter and the 
reviewer gives evidence based recommendations.   
 
1.15 OPERATIONAL DEFINITIONS 
 A systematic review: It is a review of a clearly formulated question that involves 
systematically finding, critically appraising and combining evidence from scientific 
trials and aims at minimising bias and synthesizing evidence based results 
(Rothstein, et al., 2005: 351).  
 AIDS: An abbreviation for Acquired Immunodeficiency Syndrome.   
 Antiretroviral therapy: It is the therapy given to reduce HIV transmission from 
mother to infant or to treat the infection.  In developing countries a single dose of 
nevirapine remains widely used and has been proven to reduce HIV transmission via 
breast milk during the early postpartum period when the majority of breast milk 
transmission occurs (Lehman et al 2008:2).   
 Exclusive breastfeeding: Implies that an infant receives only breast milk, and no 
other liquids or solids, not even water, with the exception of drops or syrups 
consisting of vitamins, mineral supplements or medicines (Newell, 2004:1).   
 Formula feeding: Infant milk artificially prepared with more or less similar contents 
as breast milk but does not contain colostrum. (Nolte 2007:249)   
 Meta-analysis: A summary of past research using statistical techniques to transform 
findings of studies with related/identical hypothesis into a common metric and 
calculating the overall effect, the magnitude of effect and sub sample effect of 
interventions/relationships (Burns & Groove 2007:360).  Meta-analysis statistically 
pools the results from previous studies into a single quantitative analysis that 
provides the highest level of evidence for an intervention efficacy (Conn & Rantz 
2003:400).   
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1.16 CONCLUSION 
Chapter 1 consisted of the general foundation of the systematic review.  It explicitly outlines 
how the reviewer conducted the research.  It gives an overview on what to expect 
throughout the following chapters and will act as a guide and may give an understanding to 
the readers before proceeding to the fully detailed contents of the systematic review.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
A literature review includes all written sources, usually published by scholars, relevant to the 
topic of interest.  It involves finding, reading, understanding and forming conclusions about 
the published research and theory, as well as presenting it in an organised manner (Burns & 
Groove 2005:93).  The main aim of this chapter is to conduct a critical analytical appraisal of 
the recent scholarly work on the topic.  By determining what is already known about the 
topic, the researcher can obtain a comprehensive picture of the state of knowledge (Brink, 
Van Der Walt & Rensburg 2008:66) regarding the topic of interest.   
 
2.2 DEFINITION OF EXCLUSIVE BREASTFEEDING 
According to Newell (2004:1), exclusive breastfeeding is whereby an infant is fed with only 
breast milk, and no other liquids or solids, not even water, with the exception of drops or 
syrups consisting of vitamins, mineral supplements or medicines.   
 
2.2.1 Breastfeeding and HIV 
For optimal growth, development and health, infants should be exclusively breastfed for their 
first six months.  Such infants should then receive nutritionally adequate and safe 
complementary foods, while breastfeeding continues up to 24 months and beyond.  This 
intervention is effective in cases of HIV-free breastfeeding mothers, otherwise the risk of 
mother to child transmission of HIV can double to about 40%, especially if antiretroviral 
prophylaxis and effective interventions are not followed (Newell, 2004:1).   
HIV infected mothers may consider expressing and heat treating breastmilk as an interim 
feeding strategy: 
 
 If antiretroviral drugs are temporarily not available; or 
 To assist mothers to stop breastfeeding; or 
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 In special circumstances, such as low birth weight infants or otherwise ill infants in 
the neonatal period; or 
 When the mother is unwell and temporarily unable to breastfeed or when temporary 
breastfeeding problems, such as mastitis, occur (WHO, 2009:20). 
Laboratory evidence demonstrates that heat treatment of expressed milk from HIV infected 
mothers, if correctly done, inactivates HIV.  Furthermore, there is no significant proof or 
evidence that heat treatment alters the nutritional content of the breast milk; hence, breast 
milk treated this way should be adequate to support normal growth and development WHO 
(2009:20).   
 
2.2.2 Characteristics of breast milk 
Breast milk consists of colostrum, transitional and mature milk (Nagin, 2008:1; Nolte, 
2008:233; Leroy, 2007:6-7).  Colostrum is the thick yellow milk secreted by the breasts 
during the first few days after delivery.  Generally, it is a leftover mixture of materials present 
in the mammary gland and ducts at delivery (Leroy, 2007:6; Nagin 2008:1).  According to 
Leroy (2007:6), it gradually evolves into mature milk at 3-14 days postpartum.  Colostrum 
has a low protein and fat content (Nolte, 2007:233), and contains more antibodies and white 
blood cells than mature breastmilk (Leroy 2007:6).  It aids in the formation of protective 
bacteria, or bifidus flora, in the gastrointestinal tract and also eases the movement of 
meconium (Nagin 2008:1).  According to Horvath et al., (2010:4), epidermal growth factor in 
colostrum helps to make the gastrointestinal tract less permeable to viral infection.  Nagin 
(2008:1), states that breast milk consists of water as its largest component (90%), 
oligosaccharides, vitamins, minerals, hormones, growth factors and protective agents.  It 
also has 10% solids for energy and growth (Nagin 2008:1).   
During the past decades, breastfeeding has been reinforced to improve both maternal and 
child health.  Holmes and Salvage (2007:1065), indicated immediate and long term benefits 
of breastfeeding which includes it being a cost effective intervention for child survival and 
could prevent 13-15% of child deaths in low income countries.  Breastfeeding protects 
against common infections such as diarrhoea, pneumonia, neonatal sepsis and otitis media.  
According to Newell (2004:5), a study conducted in Brazil found that infants who were not 
breast-fed were 17 times at higher risk of hospital admission (OR 16.7, 95% CI, 7.7-36.0).   
A systematic review by Hovarth et al., (2010) concluded that in HIV cases, complete 
avoidance of breastfeeding (exclusive formula feeding) is efficacious in preventing MTCT of 
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HIV but also associated with high morbidity.  The systematic review indicated that extended 
antiretroviral therapy reduces the chances of MTCT of HIV infection.  Horvath et al., 
systematic review is different from this review; their inclusion criteria consisted of trials 
whose participants had extended antiretroviral therapy and standard regime while this 
review’s trial participants were on standard regimes only which is currently on the national 
policy.  Some of the studies included in Horvath’s meta-analysis didn’t compare exclusive 
breastfeeding with exclusive formula feeding.  Therefore the reviewer aimed at focusing on 
the current health problem of exclusive breastfeeding versus exclusive formula feeding 
under a standard antiretroviral regime.   
2.3 DEFINITION OF EXCLUSIVE FORMULA FEEDING 
The process of feeding a child who is not receiving any breast milk with a diet that provides 
all the necessary nutrients that the child needs is termed ‘replacement feeding’ (Leroy 
2007:8; Newell 2004:6).   
Formula feeding involves the use of commercial infant formula that is formulated industrially 
in accordance with applicable Codex Alimentarius standards to satisfy the nutritional 
requirements of infants during the first six months of life up to the introduction of 
complementary foods (Newell 2004:1).  According to Nolte (2007:249), although the 
manufacturers of infant formulas attempt to produce a product similar to breast milk in 
quantity, some elements are only present in breastmilk, e.g. antibodies.   
Examples of commonly used modified milk formulas or breastfeeding substitutes are: 
 Whey protein-dominant starter formulas (Nan, S26, and Similac 60/40): Infants under 
four months of age should preferably have a whey-(lactalbumin) predominant 
formula.  According to Vivatvakin, Mahayosnond, Theamboonlers, Steenhout and 
Conus (2010:473), formulas predominately containing whey as a source of protein 
are considered to be similar to breast milk in terms of composition.  Whey has been 
shown to have some benefits, such as stimulating the growth of bifidobacteria.  
Furthermore, in infants, gastric emptying is more rapid after whey ingestion than after 
casein ingestion (Vivatvakin et al., 2010:473).   
 Casein-predominant starter formulas (Lactogen No. 1, SMA, and Similac): These 
formulas can be given to the larger full term newborn (birth weight ≥ 3300g) at full 
strength, as they are complete and nutritionally fully balanced.   
 Biologically pre-acidified starter formula (Pelargon): This formula is only used in 
infants with mild digestive disturbances.  It is suitable in cases where the risk of 
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contamination during preparation of bottle-feeds is high.  It has some bacteriostatic 
properties, finer and more digestible curd.  Fat, vitamin and iron content are similar to 
breast milk.   
 High protein formulas (Lactogen No. 2, Infagro): to supplement protein intake in diet 
such as cereals or fruit, especially after introduction of solids.   
 Full cream milk formulas (Klim, Nespray): appropriate for babies older than 8-12 
months who should be on a full diet.  
Adapted from Nolte (2007:250). 
 
2.4 DEFINITION OF MIXED FEEDING 
Mixed feeding is defined as the process of feeding a child breast milk and other fluids or 
food.  This can disturb the lining or cause trauma to the gastrointestinal tract of the infant, 
hence the risk of mother to child transmission of HIV is higher (Fraser, Cooper & Nolte, 
2006:366).  According to the Department of Health of the Republic of South Africa 
(2008:115), mixed feeding carries the highest risk of HIV transmission and should be 
discouraged.   
 
2.5 DEFINITION OF HIV 
Human Immune (HI) Virus is a causative virus of AIDS (Acquired Immune Deficiency 
Syndrome).  Mother to child (vertical) transmission of HIV can occur transplacentally in-
utero, intra-partum, post-partum or through breastfeeding (Cronje & Grobbler, 2003:428).  
According to Leroy (2007:8), data suggest that the first six to eight weeks of breastfeeding 
could be a high risk period for the transmission of HIV.   
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Table 2.1: Estimated absolute rates of mother-to-child transmission (MTCT) of HIV by 
timing of transmission, without interventions   
HIV transmission rate (%) 
Timing of HIV 
transmission 
No Breastfeeding Breastfeeding 
through six months 
Breastfeeding 
through 18 to 24 
months  
During pregnancy 5-10 5-10 5-10 
During labour 10-15 10-15 10-15 
During 
breastfeeding 
0 5-10 15-20 
Overall 15-25 20-35 30-45 
NB: Rates vary because of differences in maternal CD4 cell counts, RNA viral load and 
duration of breastfeeding.   
Adapted from (De Cock, Fowler, Mercier, de Vincenzi, Saba, et al., 2000:1178).   
 
Table 2.2: Rates of, and risk factors for overall mother-to-child transmission of HIV 
according to geographical location in antenatal clinics   
 URBAN RURAL 
West and Central Africa 10-15% Generally lower rates 
East Africa 15-25% 5-10% 
Southern Africa Over 40% 25-38% 
Caribbean, Central 
America, South America 
0.1-5.0% None reported 
Asia (cities/provinces of 
Cambodia, India, Indonesia 
and Thailand) 
1-5% None reported 
Eastern Europe Over 1%, likely to increase None reported 
Adapted from (Leroy 2007:3).   
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2.6 PATHOPHYSIOLOGY OF HIV 
HIV is a retrovirus, which carries its genetic information in Ribonucleic Acid (RNA). On entry 
into the body, the virus infects cells which have the CD4 antigen (Le Mone & Burke 
2000:293).  Thereafter, the virus sheds its protein coat and uses an enzyme called reverse 
transcriptase to convert RNA to Deoxyribonucleic Acid (DNA).  This viral DNA is then 
integrated into the host cell DNA and is duplicated in large numbers during normal cell 
division, infecting more lymphocytes (Le Mone & Burke, 2000:293; The Department of 
Health-South Africa, 2006b:202).   
Within the cell, the virus may remain latent or become activated to produce new RNA and 
form virions.  The virus then buds from the cell surface, disrupting its cell membrane and 
leading to destruction of the host cell.  Although the virus may remain inactive in infected 
cells for years, antibodies are produced to its proteins, a process known as seroconversion.  
These antibodies are usually detectable 6 weeks to 6 months after initial infection.  The 
antibodies seem to have little effect on the virus (Le Mone & Burke 2000:293).   
CD4 cells (also known as T4 or helper T cells) are lymphocytes (a type of white blood cell), 
which are key in both humoral and cell mediated immune responses.  These are the main 
target cells for HIV. Their numbers decrease during HIV infection, and their level is used as a 
marker of progression of the infection (Newell 2004:6; Leroy 2007:4).   
 
2.6.1 Mechanisms of transmission of HIV through breastfeeding 
Despite evidence showing that HIV is present in breastmilk (Nduati, John, Mbori-Ngacha, 
Richardson, et al., 1995:1461), mechanisms of transmission through breastfeeding remain 
incompletely understood.   
According to Newell (2004:11), after ingestion of HIV-1 infected breastmilk, infant gut 
mucosal surfaces are the most likely site of transmission.  Cell-free or cellular HIV-1 may 
penetrate to the submucosa in the presence of mucosal breaches or lesions, or via 
transcytosis through M-cells or enterocytes expressing specific receptors.   
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2.6.2 Characteristics of the mother and infant in relation to HIV 
A number of maternal and infant characteristics have been associated with an increased risk 
of HIV transmission(Horvath et al., 2010:4).  Clinical, immunological and virological factors in 
mothers, as well as infant feeding patterns, affect postnatal transmission (Leroy 2007:11).   
 
Maternal 
Recent HIV infection: (The acute viral syndrome of “primary” HIV infection.)  At this stage, 
there is usually high plasma viremia and frequently a marked decrease in CD4+ cells 
(Hoffman, Rockstroh & Kamps, 2007:26).  A low CD4+ cell count is a risk factor for late 
postnatal transmission of HIV (Horvath et al., 2010:4).  According to Leroy (2007:12), high 
levels of the virus in the blood, and probably also in breastmilk are seen in primary HIV 
infection, when the rate of postnatal transmission has been estimated to be nearly 30%.  A 
study conducted by the ZVITAMBO study group and Humphrey  (2005:704), found that 
women with CD4 cell counts less than 200 cells/µl were five times more likely to transmit 
HIV during breastfeeding compared with women with CD4 cell counts over 500 cells/µl.   
Mode of delivery:  According to (Leroy 2007:4) and Fraser et al., (2008:366), vaginal 
delivery and duration of delivery, which increase the contact between infant and infected 
cervico-vaginal secretions and blood, are linked to MTCT when compared to elective 
caesarean sections.   
Breast conditions: Recent studies confirmed the association of transmission of HIV through 
breastfeeding with maternal breast abnormalities such as breast abscess, mastitis, and 
nipple lesions (Horvath et al., 2010:4).  Clinical and subclinical mastitis has been associated 
with a transmission risk (Newell 2004:14; Leroy 2007:13; Horvath 2010:4).  According to 
Horvath (2010:4), ingestion of inflammatory cells related to the bacterial infection of the 
breast contributes to breastfeeding transmission of HIV.   
Nutritional:  According to Fraser et al., (2008:366), if a woman is more malnourished, the 
maternal disease will progress more rapidly and thus the risk for mother-to-child 
transmission will also increase.  A multivitamin supplement may improve the wellbeing and 
increase the chances of resistance to infection.  HIV/AIDS causes people to have high 
needs of certain vitamins and minerals due to their body demands to build and repair 
tissues.  Therefore, a vitamin supplement with added minerals is essential (WHO 2003:10).   
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Infant 
Gestational period of birth: Preterm birth places the infant at a higher risk of mother-to-
child transmission compared to full-term births.  This is due to the physiological differences 
between the two which includes poor development of the immune systems and well as the 
physical body parts.  This exposes them to the HI virus.  (Fraser et al., 2008:366).   
Duration and pattern of breastfeeding: Exclusive breastfeeding has been associated with 
a lower risk of postnatal transmission of HIV as compared to non-exclusive breastfeeding, 
that is, breastfeeding with formula, other fluids (water, fruit juice) or solids (baby food) (Leroy 
2001:15; Iliff, Tavengwa, Zunguza, Marinda, Nathoo et al., 2005:699). The introduction 
before the age of 3 months of solid foods or animal milk to breastfeeding infants born to HIV 
positive mothers was associated with a fourfold greater risk of postnatal transmission at 6 
months compared with exclusive breastfeeding (Iliff et al., 2005:703).   
Oral thrush: According to Newell (2004:14), oral thrush damages the mucous membranes; 
therefore, it is associated with an increased risk of transmission through breastfeeding.  It is 
difficult, however, to determine which of the two is the cause or the effect, since thrush may 
be a feature of early HIV-1 infection (Epinkin, Witkor, Satten, Adjorlolo-Johnson, Sibailly, Ou 
et al., 1997:1055).   
 
2.6.3 Detection of HIV; diagnostic tests 
There are different diagnostic tests used to detect the HIV virus.  According to Gürtler 
(1996:176), the diagnosis is normally made indirectly, that is through the demonstration of 
virus specific antibodies (anti-HIV) by ELISA or agglutination.  Reactive results are confirmed 
by western blot (immunoblot) or further specific tests such as competitive ELISA (Gürtler 
1996:176).  Direct diagnosis of HIV infection is also possible through the demonstration of 
the infectious virus (using cell culture - this is only possible in laboratories of at least 
biological safety level 3), viral antigen (p24 antigen ELISA) or viral nucleic acid (that is viral 
genome; NAT= nucleic acid testing) (Wolfgang & Korsman 2007:41).   
 
HIV antibody diagnosis-two screening assays; a screening test and at least one confirmatory 
test are required for the testing of HIV antibodies.  To exclude inadvertent mix-ups of 
samples, a second blood sample from the same patient should generally be tested.  Only 
then should the diagnosis of HIV infection be communicated to the patient in cases of 
unexpected seropositivity (Wolfgang et al., 2007:41).   
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Most screening tests are based on the ELISA principle (enzyme linked immuno sorbent 
assay).  Screening tests must be extremely sensitive to minimise the chance of yielding a 
false-negative result (Wolfgang et al., 2007:42).   
 
Enzyme linked immunosorbent assay (ELISA) screening test: This is the most widely 
used screening test for HIV infection.  It is a test for HIV antibodies and does not detect the 
virus, therefore, a client may have a negative ELISA test result early in the course of 
infection before detectable antibodies have developed (Le Mone et al., 2000:299).  This 
phenomenon is called the “diagnostic window” or “window period" (Busch & Satten 
1997:117).  Furthermore, false positives do occur; hence it is always necessary to do a 
confirmatory test which should be communicated to the patient intensively (Wolfgang et al., 
2007:44).   
 
Confirmatory assay: For confirmation of a positive or reactive test, a western blot antibody 
test or an immunofluorescence assay (IFT or IFA) is done (Wolfgang et al., 2007:44).  
According to Le Mone et al. (2000:299), this test is more reliable but more time consuming 
and more expensive than ELISA.  During this test, the patient's serum is mixed with HIV 
proteins to detect a reaction.  If antibodies to HIV are present, a detectable antigen-antibody 
response will occur (Le Mone et al., 2000:300).   
 
HIV nucleic acid testing (NAT): It usually entails a Polymerase Chain Reaction (PCR).  If 
done at birth, or from two weeks of age it will detect babies infected in utero or perinatally, 
therefore the recommended age for reliable HIV PCR testing in babies is ≥ 4 weeks (Wilson, 
Naidoo, Bekker, Cotton & Maartens, 2005:44).  According to Wolfgang et al., (2000:45), this 
detection of a viral nucleic acid (viral genome) is laboratory tested from EDTA (ethylene 
diamine tetra acid) whole blood or EDTA plasma.   
 
Rapid tests: Also known as the "bedside", "point of care" or "simple/rapid" test.  This test is 
used when results are needed urgently, for example in emergencies.  They are based on 
one of four immunodiagnostic principles: particle agglutination, immunodot (dipstick), 
immunofiltration or immunochromatography.  The results are normally available within fifteen 
to thirty minutes.  A capillary blood sample is obtained through venipunture (from a finger 
tip).  A reagent is added on the drop of blood and a "built in" internal control detects if the 
reagent is sufficient; if this control shows up, the results should not be accepted.  One band 
indicates a negative result while two indicate a positive result (excluding the control band) 
(Wolfgang et al., 2000:45).   
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CD4 (Cluster of differentiation) cell count: This is used to monitor the disease progress 
and guide treatment therapy (Le Mone et al., 2000:300; Newell 2004:4; Leroy 2007:6).   
2.7 INTRODUCTION- AIDS (Acquired Immune Deficiency Syndrome) 
AIDS is disease of the human immune system caused by HIV and results in development of 
infections including opportunistic infections such as karposi sarcoma, candida albicans, 
cytomegalovirus, pneumocystis carinni and tumours that do not affect people with working 
immune systems (WHO 2009:4). 
2.7.1 WHO clinical staging of HIV/AIDS 
The clinical staging and case definition of HIV for resource-constrained regions is based on 
clinical findings that guide the diagnosis, evaluation, and management of HIV/AIDS, and 
does not require a CD4 cell count.  This staging system is used in many countries to 
determine eligibility for antiretroviral therapy, particularly in settings in which CD4 testing is 
not available.  Clinical stages are categorized as 1 through 4, progressing from primary HIV 
infection to advanced HIV/AIDS.  These stages are defined by specific clinical conditions or 
symptoms (WHO 2009:5-6).   
 
2.8 MANAGEMENT STRATEGIES OF HIV/AIDS 
2.8.1 Non-drug management of HIV 
According to the Department of Health in the Republic of South Africa (2006a:203), 
counselling is an extremely vital part of the successful care of children with HIV infection and 
their families.  Specific matters requiring attention are: 
 The implications of the disease for the family   
 Implications of the treatment and understanding of the condition and its care.   
On completion of counselling, the family should be able to make informed decisions taking 
all this information into account.   
According to Fraser et al., (2008:667), a newly diagnosed pregnant woman must be offered 
intensive post-test counselling on the following aspects: effects of pregnancy on HIV 
infection, risk of transmission of HIV to foetus and newborn, option of termination of 
pregnancy, option for treatment in pregnancy and infant feeding.  Other aspects include 
advantages and disadvantages of breastfeeding, disclosure of results to the male partner 
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and family, the need for follow-up of both woman and child and future fertility management 
(Fraser et al., 2008:367).   
2.8.2 Drug management of HIV 
Currently, infants are given doses of antiretroviral prophylaxis.  Antiretroviral therapies 
decrease the viral load.  Such prophylaxis is designed to protect the uninfected infant while 
exposed to infection through breastfeeding.  The regimes are taken during pregnancy, 
intrapartum and postnatally by mothers, as well as infants’ post-partum.   
In 2009, the South African National AIDS Council (SANAC) Treatment Technical Task Team 
(TTT), finalised recommendations for changes to the national standard treatment guidelines 
for adult and paediatric management and treatment, as well as changes in the prevention of 
the mother-to-child-transmission of HIV (PMTCT) guidelines, moving away from 
monotherapy to dual therapy.  As announced on World Aids day 2009 by President Zuma, 
the changes to the guidelines were not to meet the Presidential mandates only, but to bring 
them in line with international recommendations and ensure the use of more efficacious 
drugs, including the phasing out of stavudine from the national antiretroviral (ART) 
programme (Serenata & Bekker, 2010:28).   
Pregnant women with a CD4 count less than 350 cells/µl meet the eligibility criteria to start 
antiretroviral therapy within two weeks of receiving their CD4 result and choosing to start 
lifelong antiretroviral therapy (ART).  If the CD4 count is more than 350 cells/µl, these 
pregnant women follow the national PMTCT guidelines, namely: 
 Zidovudine from 14 weeks - oral, 300mg 12 hourly   
 Single-dose nevirapine (NVP) - oral, 200mg at onset of labour and zidovudine - oral, 
300mg 3 hourly during labour to delivery 
 Tenofovir and emtricitabine single dose after delivery. 
If a woman presents in labour without having started either ART or the PMTCT regimen at 
14 weeks, she should still receive the single-dose nevirapine and zidovudine 3-hourly and 
tenofovir and emtricitabine as per above (Serenata & Bekker 2010:28-30).   
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Table 2.3 National regimens for infants in South Africa (Department of Health 2010:11)   
Infants Regimen Comments 
Mother on life long ART   NVP- 0.2ml/kg at birth and 
then daily for 6 weeks 
irrespective of infant feeding 
choice   
 
Mother on PMTCT   NVP-0.2ml/kg at birth and 
the daily for 6 weeks 
continued for as long as any 
breastfeeding.   
If baby is formula fed, baby 
can stop NVP at 6 weeks   
Mother did not get any ARV 
before or during delivery   
NVP-0.2ml/kg as soon as 
possible and daily for at least 
6 weeks continued for as 
long as any breastfeeding   
Assess ART eligibility for the 
mother within two weeks   
Unknown maternal status 
because orphaned or 
abandoned   
Give NVP-0.2ml/kg 
immediately.  Test infant with 
rapid HIV test. If positive, 
continue NVP for six weeks. 
If negative, discontinue NVP  
Follow-up 6-week HIV DNA 
PCR   
 
 
2.9 EXPERIENCES ON INFANT FEEDING CHOICES ACROSS THE WORLD 
Women around the world are faced with a lot of issues surrounding breastfeeding and HIV.  
In Botswana, these HIV positive women are advised not to breastfeed by the health care 
workers.  Shapiro, Hughes, Ogu, Kitch, Lockman, et al., (2009:1) (Mmabana study), 
conducted a clinical trial with a goal of comparing the suppression of the viral load at delivery 
and throughout breastfeeding among women allocated to receive different ARV regimens 
(HAART at 28 weeks).  The goal was to determine the mother-to-child transmission rate 
after six months of breastfeeding among all women who received ARV therapy.  The study 
produced the lowest rate (1%) of mother-to-child transmission in comparison with other 
studies done in Africa.  Despite this, health care workers are not convinced by these results 
and are not confident to prescribe it (Balopi 2010:1).   
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In Kwazulu-Natal, women who are HIV positive, face different challenges on infant feeding 
choices.  They are not well informed on the best feeding choice that is relevant to their socio-
economic status (Seidel, Sewpaul & Dano 2000:26-27).  Health care workers tend to 
prescribe formula milk to mothers whose last baby was known to be HIV positive, which is 
normally a special low lactose diet which is expensive, not a commercial one (Seidel et al., 
2000:30).  According to Agu, Peltzer, Seager, Setswe, Wabiri and Banyini (2009:14), infant 
feeding options should be discussed with mothers, and for each woman, the acceptability, 
feasibility, affordability, sustainability and safety (AFASS) of exclusive formula feeding 
should be discussed.  If the AFASS criteria are not met, recommendation for exclusive 
breastfeeding is, therefore, essential (Agu et al., 2010:14).  Some women disclosed to being 
abused by male family members if they chose not to breastfeed and also experienced 
negative attitudes by nurses if they chose exclusive formula feeding.  These experiences 
result in mixed feeding (Seidel et al., 2000:30).   
A qualitative study in Nigeria conducted by Sadoh (2009:31-32), found that about 21% of 
mothers could not adhere to exclusive breastfeeding after opting for it.  These mothers failed 
to exclusively breast feed their infants and ended up mixed feeding.  Twenty-three percent 
(23%) of these mothers had to recommence breastfeeding at 4 to 6 months of their infant’s 
life.  The reasons given were pressure, especially from extended family, and a case where 
the infant was said to have refused formula.  Some had not disclosed their serostatus to their 
partners.  About 77% mothers gave their babies “token” breast milk to pacify the child, 
especially in public (culturally, doing this to a crying baby is an expected behaviour).  Some 
mothers would do this when they were around friends as proof that they did not have 
anything against breastfeeding (Sadoh et al., 2009:31-32).  Mixed feeding results accounts 
for more infections than other modes of infant feeding.  In a study in Durban, infants who 
received both breast milk and other feeds were significantly more likely to be infected by 15 
months of age (36%), than those who were exclusively breast-fed (25%) or formula-fed 
(19%) (Coutsoudis 2001:380).   
 
2.10 CONCLUSION 
There are various interventions to prevent MTCT of HIV.  Post exposure prophylaxis using 
antiretroviral drugs after exposure to bodily fluids from HIV-seropositive patients is done as 
recommended per institution (Gibbon 2005:307).  Avoidance of unprotected sexual 
intercourse during pregnancy and breastfeeding mostly prevents infection (Fraser et al., 
2008:366).   
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According to Gibbon (2005:307), adherence to prevention of mother-to-child Transmission of 
HIV (PMTCT) programmes by pregnant mothers is vital.  Extended antiretroviral prophylaxes 
to the infant (nevirapine alone, or nevirapine with Zidovudine) are efficacious in preventing 
transmission (Horvath et al., 2010:2).  The mode of delivery has an effect on the infection 
rate.  Caesarean section delivery before labour and before ruptured membranes (elective 
caesarean section) can prevent MTCT of HIV (Horvath et al., 2010:3).  Appropriate infant 
feeding choices are important; complete avoidance of breastfeeding is efficacious in 
preventing MTCT of HIV, but mixed feeding is associated with high transmission rates and 
replacement feeding is associated with high morbidity (Horvath et al., 2010:2; Coovadia et 
al., 2007:1107).  According to Thior et al., (2006:795), exclusive breastfeeding with abrupt 
early weaning after 3-6 months, pasteurization, hot water bath, and microbicidal treatment of 
breast milk with alkyl sulphates  have been  proposed as methods to make breastfeeding 
safe.   
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CHAPTER 3 
RESEARCH METHODS 
 
3.1 INTRODUCTION 
Research methodology focuses on all the related processes of review execution.  Validity 
and reliability of data collection tools is ensured hence the quality of the study (Higgins & 
Green 2006:79; Brink et al., 2008:11).  This chapter elaborates this research methodology 
intensively in this study.   
 
3.2 RESEARCH DESIGN 
It is vital for a researcher to formulate a research question that is “understandable” and 
researchable so that research designs, data collection and analysis may be possible (Brink 
et al 2008:52).  Systematic reviews have been found to be the highest ranked source of 
evidence-based research ‘for efficacy of interventions’ (Glasziou et al., 2001:53).  According 
to Higgins and Green (2006:98-99), a small effect can be detected through systematic 
reviews.  Individual studies may not have significant outcomes. However, combining two or 
more homogenous studies through meta-analyses results can improve detection of 
treatment effects.   
Meta-analysis is now used in numerous scientific disciplines, summarising quantitative 
evidence from multiple studies (Rothstein et al., 2005:1).  Systematic reviews are then 
advantageous to health care workers, policy makers, patients and clients since they manage 
fewer quantities of data that might vary.  According to Higgins and Green (2006:15), when 
numerous, homogeneous, primary researched trials are all summarised into one form; it is 
easier to understand and manage the results.  Higgins and Green (2006:16) state that meta-
analyses of heterogeneous studies in systematic reviews are possible and a random effects 
model is used to accommodate heterogeneity.   
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3.3 AIM 
The researcher’s aim of the systematic review is to compare the effectiveness of exclusive 
breastfeeding versus that of formula feeding and/ or mixed feeding with the use of 
antiretroviral prophylaxis in the prevention of HIV-1 transmission from mother to child.   
 
3.4 OBJECTIVES 
Brink et al., (2008:79) define objectives as ‘clear, concise, declarative statements that are 
written in the present tense and usually focuses on one or two variables and indicate 
whether such variables can be identified, analysed or described.  The objectives are as 
follows: 
 
3.4.1 Primary objective 
1. To evaluate the evidence on exclusive breastfeeding in the prevention of mother-to-child 
transmission of HIV-1 (HIV infection) as compared to exclusive formula feeding and/ or 
mixed feeding with the use of antiretroviral prophylaxis.   
 
3.4.2 Secondary objectives 
1. To compare the mortality rates in exclusive breast-fed versus formula and/or mixed-fed 
infants.   
2. To determine the HIV-free survival at 24 months in exclusive breast-fed versus formula 
and/ or mixed-fed infants.   
 
3.5 HYPOTHESIS 
It was hypothesised that exclusive breastfeeding (with the use of antiretroviral prophylaxis) is 
more effective than formula feeding and/ or mixed feeding in the prevention of HIV-1 
transmission of mother to child, morbidity and better chances of HIV free survival.   
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3.6 SELECTION CRITERIA FOR STUDIES 
3.6.1. Search strategy for identification of studies 
Health databases including PUBMED/MEDLINE (Medical Literature Analysis and Retrieval 
System Online), EMBASE, (Excerpta Medica Database), CINAHL (Cumulative Index of 
Nursing and Allied Health), Cochrane Clinical Trial Register and Cochrane HIV/AIDS 
Group/CENTRAL (Cochrane Central Register of Controlled Trials) were searched 
extensively.  A search of electronic journals which includes the Southern African Journal of 
HIV medicine (SAJHIV), HIV Medicine Journal, African Journal of AIDS Research (AJOR) 
and American Journal of Public Health was conducted.  Textbooks on breastfeeding and 
HIV, as well as HIV/AIDS conference proceedings were also accessed.  A follow up from 
reference lists was done to source more data.  The medical search headings (MeSH terms) 
that were used for searching data included: exclusive breastfeeding and HIV, infant feeding, 
interventions, prevent, HIV transmission, postnatal HIV transmission, randomised, 
randomized, randomisation and randomization.   
In addition, experts in the field of paediatrics, midwifery and HIV/AIDS were contacted for 
more relevant information and referral to other sources.  There were no limitations to 
language or date during the search and the articles were peer reviewed publications, 
unpublished data and theses.  The search period ranged between December 2010 and 
February 2011.   
A general search strategy as shown below was adapted for each one of the databases:   
1 Breastfeeding 
2 “Breastfeeding (exclusively)”/ 
3 (Exclusive breastfeeding$ or breastfeeding exclusively$ or exclusive breast feeding$).tw. 
4 Exclusive formula feeding/ 
5 Formula feeding exclusively 
6 Mixed feeding$.tw. 
7 or/1-6 
8Infant feeding/ 
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9 Infant feeding challenges/ 
10 HIV/ 
11 Postnatal HIV transmission/ 
12 Mother to child transmission of HIV / 
13 interventions / 
14 HIV prevention / 
15 ((interventions or prevention$) adj3 (infant feeding postnatal transmission or mother-to-
child transmission via infant feeding)).tw. 
16 HIV free survival/ 
17 HIV infection/ 
18 HIV free / 
19 Clinical trials/ 
20 Trials.tw. 
21 clinical studies/ 
22 (Clinical trials or clinical studies).tw. 
23 (randomised or randomized or randomisation or randomization).tw.23 or 8-23  
 
3.6.2 INCLUSION CRITERIA AND ELIGIBILITY FOR STUDIES 
All the studies meeting the inclusion criteria studies had the PICO acronym (Participant, 
Intervention, Comparison, Outcomes).  A well formulated question comprises of these four 
parts (Glasziou et al., 2001:14).  This is demonstrated below: 
3.6.2a Population/ Participants or patient group  
It refers to infants that were HIV-1 exposed via breastfeeding and exclusive formula feeding.   
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3.6.2b Intervention (treatment group: exclusive breastfeeding) 
In this review, experimental interventions from selected studies included exclusive 
breastfeeding (six months duration under a certain antiretroviral prophylaxis).   
 
3.6.2c Comparison   
Formula feeding (under a certain antiretroviral prophylaxis) was compared to exclusive 
breastfeeding.  None of the included studies compared exclusive breastfeeding to mixed 
feeding.   
 
3.6.2d Outcomes (prevention of HIV transmission from mother to child)   
Primary outcome 
1. HIV infection as measured up to 24 months of life   
Secondary outcomes 
1. Infant mortality as measured up to 24 months   
2. HIV-free survival as measured up to 24 months   
 
Two reviewers: (AP, OK) independently assessed titles identified in the search strategy.   
If a title was considered to be relevant, its abstract was reviewed to determine whether the 
article might meet predisposed eligibility criteria (as above).  An article that did not meet 
eligibility criteria was rejected.  If the title or abstract left room for doubt that the article 
cannot definitely be rejected, the full text of the article was obtained.  Full text articles which 
did not meet the inclusion criteria were excluded.  If the article was not rejected, information 
from it may then be formally extracted using the data extraction form.  Disagreements about 
the inclusion of studies were resolved by referring back to the original article and discussion 
until consensus was established between the two reviewers.  
 
Studies included in the systematic review were those with eligible study designs, such as 
randomised controlled trials and cohort studies with good quality evidence.  The research 
design used was a systematic review with meta-analysis.  Quality assessed studies: Thior, 
(2006), Peltier, (2009) and Nduati, (2000) were statistically combined and analysed on Rev 
Man 5.1.0 into a single quantitative analysis.  The aim was to provide the best level of 
evidence for efficacy of therapeutic interventions.   
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3.7 EXCLUSION CRITERIA 
As stated initially in the protocol, studies showing an attrition rate of more than 15% were to 
be excluded.  Due to longer duration of studies and a possibility of a high attrition rate, a 
minimum of 20% loss to follow up was considered.  Studies not reporting outcomes of 
interest were excluded.   
 
3.8 DATA EXTRACTION AND MANAGEMENT 
A data extraction form was used as a tool to determine which studies met the inclusion 
criteria.  It consisted of all the predetermined inclusion criteria.  Data retrieved included: 
study design (RCTS, cohort), study population (infants), interventions (exclusive 
breastfeeding), comparisons (exclusive formula and mixed feeding), outcomes (Infant HIV, 
Infant mortality and HIV free survival), setting, socio- economic status, date of study, sample 
size, number lost to follow up, risk of bias assessment, type of analysis and results  . 
The two reviewers independently extracted the data from the articles. Notes were then 
compared. Where there was a disagreement, the two reviewers discussed and reached 
consensus. A third reviewer was available for further clarification and input.   
A data extraction form was piloted using two articles to determine if the actual study could be 
feasible using the same data extraction form.  This enabled the researcher to determine if 
the systematic review will be feasible.  A pilot study identifies the type of data necessary for 
meta-analyses.  According to Lancaster, Dodd and Williamson (2004:307-312), a pilot study 
is a small experiment designed to test logistics and gather information prior to a large study.  
It improves the quality of the efficiency of the latter, and can reveal deficiencies in the design 
of a proposed experiment or procedure and these can then be addressed before the time 
and resources are then expanded into large scale studies.   
 
3.9 ASSESSMENT OF METHODOLOGICAL QUALITY 
To ensure methodological quality, two reviewers independently assessed the studies using 
the Cochrane ‘risk of bias’ assessment tool.  The six areas that were considered in 
assessing risk of bias were: sequence generation; allocation concealment; blinding; 
incomplete outcome data assessment; selective outcome reporting and other risks of bias, 
using the ratings: low risk, high risk and unclear to each domain by the reviewers (AP) and 
(OK) independently.  Any disagreements were resolved through discussions.  These 
judgements were entered into a ’Risk of bias’ table in Review Manager 5.1.0 (Review 
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Manager 2011) with a brief rationale for the judgements.  Review Manager Version 5.1.0 
then formulated the two tables: Risk of bias graph and Risk of bias summary (Cochrane 
Collaboration 2009).  Table 3.1 below shows a Cochrane risk of bias assessment tool.   
 
 
Table 3.1: Cochrane assessment tool for assessment of methodological quality   
(Cochrane Collaboration 2009) 
DOMAIN REVIEW AUTHOR’S 
JUDGEMENT 
LOW 
RISK 
 
HIGH 
RISK 
UNCLEAR
Sequence generation Was the allocation sequence 
adequately generated? 
   
Allocation 
concealment 
Was allocation adequately 
concealed? 
   
Blinding of 
participants, 
personnel and 
outcome assessors  
Assessment should 
be made for each 
main outcome (or 
class of outcome) 
Was knowledge of the allocation 
intervention adequately prevented 
during the study? 
   
Incomplete outcome  
Data assessments 
should be made for 
each main outcome 
(or class of outcome)
Were incomplete outcome data 
adequately addressed? 
   
Selection outcome 
reporting 
Are reports of the study free of 
suggestion of selective outcome 
reporting? 
   
Other sources of 
bias 
Was the study apparently free of 
other problems that could put it at a 
high risk of bias? 
   
 
Table 3.1 shows the Cochrane methodological quality/risk of bias assessment tool that was 
used for data validation.  Each question or domain was rated as either high risk, low risk or 
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unclear.  The following paragraph explains in detail for each criteria how it was judged as 
high risk, low risk or unclear. 
 
Random sequence generation  
For each included study, we described the method used to generate the allocation sequence 
in sufficient detail to allow an assessment of whether it would produce comparable groups.  
We assessed the method as: 
• low risk of bias (any truly random process, e.g. random number table; computer random 
number generator); 
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic 
record number); or 
• unclear risk of bias. 
 
Allocation concealment  
We described for each included study the method used to conceal allocation to interventions 
prior to assignment and assessed whether intervention allocation could have been foreseen 
in advance of, or during recruitment, or changed after assignment.  We assessed the 
methods as: 
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed 
opaque envelopes); 
• high risk of bias (open random allocation; unsealed or non-opaque envelopes; alternation; 
date of birth); 
• unclear risk of bias. 
 
Blinding of participants and personnel (checking for possible performance bias) 
We described for each included study the methods used, if any, to blind study participants 
and personnel from knowledge of which intervention a participant received.  We considered 
that studies were at low risk of bias if they were blinded, or if we judged that the lack of 
blinding would be unlikely to affect results.  Assessing blinding separately for different 
outcomes or classes of outcomes was done. 
Methods were assessed as:  
• low, high or unclear risk of bias for participants; 
• low, high or unclear risk of bias for personnel. 
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Blinding of outcome assessment (checking for possible detection bias) 
We described for each included study the methods used, if any, to blind outcome assessors 
from knowledge of which intervention a participant received.  Blinding was assessed 
separately for different outcomes or classes of outcomes.   
We assessed methods used to blind outcome assessment as: low, high or unclear risk of 
bias. 
 
Incomplete outcome data (checking for possible attrition bias due to the amount, 
nature and handling of incomplete outcome data)   
For each included study, and for each outcome or class of outcomes, a description of the 
completeness of data including attrition and exclusions from the analysis were made.  We 
stated whether attrition and exclusions were reported and the numbers included in the 
analysis at each stage (compared with the total randomised participants), reasons for 
attrition or exclusion were reported.  Where sufficient information is reported, or can be 
supplied by the trial authors, we will re-include missing data that was included in the analysis 
that the reviewer made.   
Methods were assessed as: 
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across 
groups and is unlikely to influence the outcome; missing data have been imputed using 
appropriate methods); 
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as 
treated’ analysis done with substantial departure of intervention received from that assigned 
at randomisation); 
• unclear risk of bias.   
 
Selective reporting (checking for reporting bias) 
The chances of selective outcome reporting bias will be investigated.  An assessment of the 
methods as either low risk, high risk and unclear risk of bias as clarified below was 
performed.   
• Low risk of bias (where it is clear that all prespecified outcomes of the study and all 
expected outcomes of interest to the review have been reported); 
• high risk of bias (where not all the  pre-specified outcomes of the study have been 
reported; one or more reported primary outcomes were not pre-specified; outcomes of 
interest are reported incompletely and so cannot be used; study fails to include results of a 
key outcome that would have been expected to have been reported); 
• Unclear risk of bias. 
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Other bias (checking for bias due to problems  
We described for each included study any important concerns we had about other possible 
sources of bias in each included study.   
The reviewers independently assessed whether each study was free of other problems that 
could put it at risk of bias: 
• low risk of other bias; 
• high risk of other bias; 
• unclear whether there is risk of other bias.   
 
Overall risk of bias 
Explicit judgments about whether studies are at high risk of bias were done, according to the 
criteria given in the Handbook (Higgins 2011:203).  With reference to the above, we 
assessed the likely magnitude and direction of the bias and whether we consider it, is it likely 
to impact on the findings.  We explored the impact of the level of bias through undertaking 
sensitivity analyses.   
 
3.10 MEASUREMENT OF TREATMENT EFFECTS 
The effect measure of choice was the relative risk (RR) with a 95% confidence interval (CI) 
for dichotomous data using and a p-value of 0.05.  A random effects model was used to 
accommodate potential bias and heterogeneity.  Studies were heterogeneous, the outcomes 
were measured at different months across the included studies and there could be 
inconsistencies.  In homogeneous studies, a fixed effect model is used.  To demonstrate and 
illustrate the effects of interventions, forest plots were used.   
 
3.11 UNIT OF ANALYSIS ISSUES 
The included studies, Thior (2006) and Nduati (2000), randomly assigned participants to 
either exclusive breastfeeding or formula feeding.  Peltier (2009) conducted an interventional 
cohort study and the participants chose the feeding option for themselves. No random 
allocation of the intervention was used.   
 
3.12 DEALING WITH MISSING DATA 
There were attrition levels in the included studies. Sensitivity analysis was incorporated 
during meta-analysis to explore if there could be a variance between the results which 
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should be taken into consideration.  The included studies have all been analysed on an 
intention to treat basis when the trials were conducted.  All the participants were analysed 
according to the group they were allocated to regardless of whether or not they received the 
allocated treatment or completed the study.  The attrition number in each was calculated as 
the number randomised in the study minus the number whose outcomes of interest are 
missing.   
 
3.13 DATA ANALYSES AND SYNTHESIS 
Data was quantitatively analysed.  A statistical tool, Review Manager Version 5 (RevMan 
5.1.0) designed by the Cochrane Collaboration was used was used for meta-analyses.  
Meta-analyses were performed through statistical combination of outcomes from the three 
heterogeneous studies using the random effects model and standard mean difference.  
Included studies were intensively screened for methodological quality and combined to 
statistically analyse the data, hence increasing chances of detecting an effect.  An 
advantage of applying meta-analysis is increasing power in small studies and this can detect 
small effects (Deeks et al., 2006:98).  When two or more are combined, there is a high 
chance of detecting an effect (Deeks et al., 2006:97).  In addition, it helps in answering 
questions that are not reflected by individual studies and resolving arguments arising from 
conflicting studies.  This statistical analysis of findings allows the degree of conflict to be 
formally assessed for different results to be explored and quantified.   
The effective measure of choice was a risk ratio with 95% confidence intervals for 
dichotomous data using a random effect meta-analysis.  In cases where there are no 
heterogeneity suspected, a fixed effect method using weighed mean difference (WMD) for 
continuous or dichotomous data would be the model of choice.  (Deeks et al., 2006:97-132).  
Forest plots were then used to demonstrate the effect of interventions.   
 
3.14 ASSESSMENT OF HETEROGENEITY 
According to Deeks et al., (2006:136) heterogeneity occurs when the included studies show 
diversity of participants, methodology, outcomes or statistics.  If confidence intervals for the 
results of individual studies have a poor overlap, this generally indicates the presence of 
statistical heterogeneity (Deeks et al., 2006:137).  Inconsistency gives incorrect and 
unreliable results in the end, especially if meta-analysis is mistakenly done.   
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To overcome this, the effective measure of choice was a risk ratio with 95% confidence 
intervals for dichotomous data using the random effects model.  A statistical test strategy; 
the I-squared test (I²) was used to measure heterogeneity using the formula I² = (Q–df / Q) X 
100%.  Q implies chi-squared statistics while df is the degrees of freedom.  This describes 
the percentage of the variability in effective estimate that is due to heterogeneity rather than 
chance.  Proportion of variation, in effect, estimates between the included studies which 
were due to heterogeneity.  An I-squared test of 0-40%, 41-60%, 61-75% and 76-100% were 
considered as not important, moderate, substantial and considerable heterogeneity 
respectively. 
The p-value (P stands for probability) was used to determine the significance of 
heterogeneity.  (Deeks et al., 2006:137).  A p-value of 0.1 was used as an indicator of 
heterogeneity.  (Deeks et al., 2006:137).  Heterogeneity was also explored through subgroup 
analyses.  Forest plots were then used to demonstrate the effect of interventions. 
 
3.15 SUBGROUP ANALYSIS AND INVESTIGATION OF HETEROGENEITY 
Heterogeneity was explored through subgroup analysis.  Due to the wide variance in 
variables across studies, it was important to ‘split’ the studies so as to investigate 
heterogeneous results (Deeks et al., 2006:141).  During subgroup analysis, the studies were 
grouped according to the consecutive ages that the outcomes were measured (6, 7, 9) or of 
the infants developmental stages (6, 9, 18 and 24 months).  Subgroups were limited so as 
not to produce misleading results.   
 
3.16 SENSITIVITY ANALYSIS 
Sensitivity analysis was incorporated during meta-analysis to determine if the same results 
could be obtained.  This was due to the fact that the outcomes of different trials included in 
the study were measured at different months therefore; there could be unknown 
inconsistencies between results across studies.  Thior (2006) measured their outcomes at 7, 
and 18, Peltier (2009) at 9 months and Nduati (2000) at 6, 18 and 24 months.  Deeks et al., 
(2006:151), elaborates that a re-analysing of the data is performed using a range of results 
for studies where there may be uncertainty about the results and this cannot be resolved by 
contacting the authors.   
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3.17 VALIDITY AND RELIABILITY 
Reliability is the consistency and dependability of a research instrument to measure a 
variable and yield the same results if used repeatedly over time on the same person or if 
used by two researchers (Brink et al., 2006:164-165).   
Validity can either be internal or external.  External validity is the degree to which study 
results can be generalised to other people and other research settings.  Internal validity 
refers to the degree to which changes in the dependent variable (effect) can be attributed to 
the independent or experimental variable (cause).  Instrument validity seeks to ascertain 
whether an instrument accurately measures what it is supposed to measure, given the 
context in which it is applied (Brink et al., 2006:159-165).   
Data quality of included studies was assessed in the analysis.  Studies were validated 
through assessing whether their designs and conduct are likely to prevent systematic errors 
or biases.  To ensure this, a standardised Cochrane assessment tool was used.  The three 
reviewers (AP), (OK) and (KH) are knowledgeable in systematic reviews and have attended 
research methods courses.  In addition Prof. Hofmeyr, an expert in obstetrics, HIV/AIDS 
trials and systematic reviews was repeatedly consulted.   
According to Higgins and Green (2006:81-82), the Cochrane assessment tool ‘investigates’ 
the sources of systematic bias in studies screened which are selection bias, performance 
bias, attrition bias and detection bias.  The chi-squared and I-squared test were used for the 
assessment of heterogeneity.   
 
3.18 ETHICAL CONSIDERATIONS 
Permission to conduct this study was sought from the Ethics Committee at Stellenbosch 
University.  A panel of research methodology experts in the Division of Nursing reviewed the 
protocol and permission for the study to proceed was given by the Ethics Committee.  The 
registration number assigned to the protocol is N10/11/391.  All trials used in the review 
were registered by their relevant Ethics Committee.   
 
3.19 DISSEMINATION OF RESULTS 
A report in thesis form will be submitted as part of the fulfilment of a Master’s of Nursing 
(MCur) degree to Stellenbosch University.  The researcher will present the results at a 
relevant conference and will publish it in an accredited peer reviewed journal. Reader 
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friendly copies will be distributed to a variety of educational places and health institutions.  
These will include universities, community health centres, policy makers and community 
libraries or newspapers.   
 
3.20 LIMITATIONS 
The systematic review was based on relatively few articles and methodological weakness 
could influence conclusions of the study.  There was also considerable variability across 
studies included in terms of timing used in measuring the outcomes possibly limited 
comparisons of results.   
3.21 CONCLUSION 
Chapter 3 gave a detailed elaboration of the research design and gives the reader a clear 
overview on how the research was conducted.   
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CHAPTER 4 
RESULTS 
 
4.1 INTRODUCTION 
This chapter presents the results of the systematic review.  The synthesized data is 
managed and presented in tables and graphs.  The reviewer discusses the results with 
relevance to the hypothesis and the research question. 
Data analysis in quantitative studies such as systematic reviews basically entails that the 
analyst breaks down data into constituent parts to obtain answers to the research questions 
and to test the hypothesis.  An analysis does not, in itself, answer the research question, 
therefore, the reviewer is required to interpret and give meaning to the results, thus 
answering the research question (De Vos, 2000:203). 
 
4.2 OUTCOME OF SEARCH STRATEGY 
4.2.1 Results of the search 
Flow diagram 4.1 on the next page shows the results of the search strategy from PubMed, 
CINAHL, EMBASE and CENTRAL.  The search brought about 243 citations.  HIV/AIDS is a 
widely published subject and about 184 citations were sidelined because of irrelevancy.  The 
59 remaining citations generally indicated that the content was concerned about 
breastfeeding and other feeding options in relation to HIV/AIDS.  An abstract of each citation 
was obtained of which 45 were excluded for not being actual studies; either news reports, 
comments or newsletters.  Therefore, 14 full text articles were reviewed thoroughly.  Eleven 
articles were excluded for various reasons such as high risk bias, irrelevant interventions 
and outcomes as shown in this chapter under ‘table of excluded studies’.  Only 3 articles met 
the inclusion criteria Thior (2006), Nduati (2000) and Peltier, (2009).   
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Figure 4.1: Flow diagram of results of various databases.  
Extensive search of 
electronic databases 
brought 243 articles 
consisting of titles and 
184 excluded due to 
irrelevant information, 
duplicates or not 
reporting outcomes 
of interest.
59 citations reported 
exclusive breastfeeding/ 
formula or mixed feeding 
in relation to HIV. 
45 abstracts excluded for 
not being actual studies: 
news reports of studies, 
comments and newsletters. 
14 full text 
articles were 
reviewed 
3 studies met 
the inclusion 
criteria 
11 studies excluded after 
review of full text 
Table 4.7 shows the list 
and reasons for exclusion 
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4.2.2 Included studies 
The tables below are a summary of the search results, included studies and their 
characteristics.  The included studies were conducted in Botswana, Kenya and Rwanda.  
The sample size of all the participants included in the systematic review analyses was 2112.  
The included studies were all published in the English language and were published in peer 
reviewed accredited journals.   
 
Table 4.1: Studies included in the review 
Study ID Citation 
Thior, 2006 Thior, I., Lockman, S., Smeaton, L., Shapiro, R., Wester, C. ., 
Stevens, L., Moffat, C., Arimi, P., Ndase, P., Asmelash, A., Leidner, 
J., Novitsky, V., Makhema, J. & Essex, M. (2009). Breastfeeding 
plus infant zidovudine prophylaxis for six months vs. formula 
feeding plus infant zidovudine for 1 month to reduce mother-to-
child HIV transmission in Botswana. A randomised trial: The Mashi 
study.  Journal of infectious diseases society of America, 
199(3):414-418 
Nduati, 2000 Nduati, R., John, G., Mbori-Ngacha., Richardson B., Overbaugh, J., 
Mwatha, A., Ndinya-Achola, J., Bwayo, J., Onyango, F. E., Hughes, 
J. & Kreiss, J (2000). Effect of breastfeeding and formula feeding 
on transmission of HIV-1: A Randomised Clinical trial. Journal of 
infectious diseases society of America, 283(9):1167-1174 
Peltier, 2009 Peltier, C.A., Ndayisaba, G.F., Lepage, P., Van Griensven J., Leroy 
V., Pharm, C. O., Ndimubanzi, P. C., Courteille, O. & Arendt, V. 
(2009). Breastfeeding with maternal antiretroviral therapy or 
formula feeding to prevent HIV postnatal mother-to-child 
transmission in Rwanda. AIDS 2009, 23:2415-2423  
 
Table 4.1 shows the three published studies, Thior (2006), Nduati (2000) and Peltier (2006), 
that were included in the analysis. They were published in accredited journals.  The studies 
were screened for any methodological flaws that could give misleading results before 
inclusion as described in chapter 3.  Chapter 4 clearly indicates how each study was 
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assessed for inclusion, intensively screened for validity and reliability to eliminate high risk 
bias.   
 
4.2.2.1 Characteristics of included studies 
Table 4.2a: Characteristics of included study: Thior (2006) 
Methods 2x2 Factorial Randomised clinical trial 
Participants 1200 women who benefited from the HAART programme at 
different stages before delivery were randomised for two feeding 
options; 598 exclusive breastfeeding and 602 exclusive formula 
feeding before delivery.  1193 reached delivery of which 588 (7 
stillbirths) were assigned to exclusive breastfeeding 591 (7 
stillbirths) formula feeding. A total of 1079 live infants proceeded to 
the assigned feeding option 
Interventions The latter was designed as a superiority study to detect differences 
between exclusive breastfeeding plus infant zidovudine prophylaxis 
for 6 months and exclusive formula feeding plus infant zidovudine 
prophylaxis for 1 month. There was a total of 93.0% of full 
adherence to exclusive formula feeding as reported by mothers 
and a total of 17.5% by month 5 to exclusive breastfeeding while 
75.5% reported mixed feeding and 7.5% reporting predominant 
breastfeeding 
Comparisons Exclusive breastfeeding plus infant zidovudine prophylaxis for 6 
months vs. exclusive formula feeding and infant zidovudine 
prophylaxis for 1 month   
Outcomes Infant HIV infection, Infant mortality and HIV infection 
Timeline The outcomes were measured at 7 months and 18 months of age 
 
Table 4.2a is a summary of the included study Thior (2006).  It was conducted in Botswana 
with an aim of detecting the differences between EBF and EFF under ARV prophylaxis.  The 
outcomes were HIV infection, infant mortality and HIV-free survival.   
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Table 4.2b: Risk of bias table Thior (2006) 
DOMAIN/ 
QUESTION 
LOW 
RISK 
HIGH 
RISK 
UNCLEAR DESCRIPTION 
Sequence 
generation? 
√   1200 HIV pregnant women were 
randomly assigned to exclusive 
breastfeeding and exclusive 
breastfeeding during enrolment at 34 
weeks gestation 
Allocation 
concealment? 
√   Centralised or pharmacy-controlled trial 
Blinding of 
participants, 
personnel and 
outcome 
assessor? 
√   Despite study participants and 
researchers being unaware of the 
feeding options until 34 weeks 
gestation, after that it was impossible to 
blind the participants. It is unclear 
whether outcome assessors were 
unblinded 
Incomplete 
outcome data 
adequately 
addressed? 
√   Data assessments were made for each 
main outcome: HIV infection, infant 
mortality and HIV-free survival. 
Intention to treat analysis was done. All 
the 1079 enrolled infants were included 
in the analysis despite the loss to follow 
up. The loss of follow up was generally 
less than 15%. In the breastfeeding 
arm it was 4.3% and 9.0% while in the 
exclusive breastfeeding arm it was 
2.7% and 9.0% at 7 and 18 months age
Study free of 
selective 
outcome 
reporting? 
√   There was no evidence of reporting of 
only desirable results   
Free of other 
bias? 
√   Generally there were no other signs of 
any biases in the study 
 
Quality assessment was performed for the included study, Thior (2006).  The risk of bias 
was low.  It was a study of good methodological design and suitable for meta-analysis.   
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Table 4.3a: Characteristics of included study: Nduati (2000) 
Methods Randomised controlled trial 
Participants 425 HIV-1 seropositive, antiretroviral-naive pregnant women at 32 
weeks were enrolled into two arms. 212 were assigned to 
exclusive breastfeeding and 213 for exclusive formula feeding 
arm. From the exclusive breastfeeding arm, 15 babies were lost 
due to miscarriages, maternal death, loss to follow up before 
delivery and stillbirths before delivery resulting in 197 live new 
born singletons. In the exclusive formula feeding arm, 9 were lost 
due to the above mentioned reasons resulting in 204 live 
singletons and first twins. A total of 401 were included in the 
analysis  
Interventions Exclusive breastfeeding and exclusive formula feeding both 
without infant prophylaxis, only maternal HAART 
Comparisons Exclusive breastfeeding vs. Exclusive formula feeding  
Outcomes Infant HIV infection, infant mortality and HIV-free survival   
Timeline Outcomes measured at 6 and 24 months 
 
Table 4.3a summarises a study by Nduati (2000).  This randomised controlled trial 
conducted in Rwanda compared exclusive breastfeeding versus exclusive formula feeding.  
The total number of infants included in the analysis was 401.  The outcomes were HIV 
infection, Infant mortality and HIV-free survival measured at 6 and 24 months.   
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Table 4.3b Risk of bias table: Nduati (2000) 
DOMAIN/ 
QUESTION 
LOW 
RISK 
HIGH 
RISK 
UNCLEAR DESCRIPTION 
Sequence 
generation? 
√   The randomisation method was 
used 
Allocation 
concealment? 
√   Computer generated allocation to 
either exclusive breastfeeding or 
exclusive formula feeding 
Blinding of 
participants, 
personnel and 
outcome 
assessor? 
√   Study participants and 
researchers were unaware of the 
feeding options until 32 weeks 
gestation, after that it was 
impossible to blind the 
participants. It is unclear whether 
researchers and outcome 
assessors were unblinded 
Incomplete 
outcome data 
adequately 
addressed? 
√   Data assessments were made for 
each main outcomes; HIV 
infection and infant mortality. 
Intention to treat analysis was 
done. The loss to follow up after 
delivery was 6.0% and then a 
total of 17% over two years and 
were all included in the analysis   
Study free of 
selective outcome 
reporting? 
√   There was no evidence of 
reporting bias or reporting of only 
desirable results   
Free of other 
bias? 
√   Generally there were no other 
signs of any biases in the study 
 
The risk of bias was performed for methodological quality for the included study Nduati 
(2000) as shown by table 4.2b.  The results indicated that the study had few methodological 
flaws and bias.  It was therefore suitable to be used for meta-analysis. 
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Table 4.4a Characteristics of included study: Peltier (2009)  
Methods Non randomised interventional Cohort study 
Participants 562 HIV positive pregnant women were enrolled into the study. 
240 chose breastfeeding with HAART and 322 chose formula 
feeding. There were 551 deliveries of which 5 died from before 
two days and 14 were stillbirths. 532 infants were then enrolled; 
227 on breastfeeding and 305 on the formula feeding arm 
Interventions Exclusive breastfeeding with maternal HAART and formula 
feeding  
Comparisons Exclusive breastfeeding vs. Exclusive formula feeding 
Outcomes Infant HIV infection, infant mortality and HIV-free survival 
Timeline Outcomes measured at 9 months 
 
Table 4.4a is a detailed summary of the included study conducted in Kenya by Peltier 
(2009). The non-randomised Interventional cohort study enrolled 562 pregnant women who 
chose infant feeding options for themselves.  532 infants were included in the study and the 
outcomes measured at 9 months of age were infant HIV infection, infant mortality and HIV-
free survival. 
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4.4b Risk of bias table: Peltier (2009)   
DOMAIN/ 
QUESTION 
LOW 
RISK  
HIGH 
RISK 
UNCLEAR DESCRIPTION 
Sequence 
generation? 
 √  Non randomised intervention 
cohort study 
Allocation 
concealment? 
 √  Patients chose their own suitable 
infant feeding option 
Blinding of 
participants, 
personnel and 
outcome 
assessor? 
 √  No blinding was done to both the 
participants and personnel. It is 
unclear whether outcome 
assessors were blinded or not 
Incomplete 
outcome data 
adequately 
addressed? 
√   Intention to treat analysis was 
done and all the outcome data was 
assessed.  There were 15 infants 
lost to follow up from the exclusive 
breastfeeding arm and 3 from the 
exclusive formula feeding arm, 
thus 3.4% loss   
Study free of 
selective outcome 
reporting? 
√   There was no evidence of 
reporting only positive results   
Free of other 
bias? 
√   There are no other signs of any 
biases in the study 
 
The risk of bias table for methodological quality assessment was performed for the included 
study by Peltier (2009).  The study had fairly good methodological quality.  Randomisation, 
allocation concealment and blinding were impossible because of the study design (cohort 
study).   
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4.2.2.2 Excluded studies 
Table 4.5 Characteristics of excluded studies 
Study ID Reasons for exclusion 
1. Bedri (2008)  
2. Dabis (1999) 
3. Kumwenda 
(2008) 
4. Lehman (2008) 
5. Kilewo (2008) 
6. Guay (1999) 
7. Violari (2008) 
8. Homsy (2010) 
Primary objectives, intervention and comparison were different 
from the researcher’s as stated in the protocol. In all the studies, 
trialists’ aims were to test the efficacy of antiretroviral therapies in 
two exclusive breastfeeding arms. They  compared exclusive 
breastfeeding, plus an antiretroviral vs. exclusive breastfeeding 
with an extended dose antiretroviral or a different antiretroviral. 
The antiretroviral therapies varied across the studies, duration or 
timing of therapy. Despite this, all the studies had the same 
outcomes as the review’s, HIV infection 
9. Iliff (2005) It was a sub-study of another trial which gave HIV positive 
breastfeeding women vitamin A after delivery. The aim was to find 
out the impact of it on maternal and neonatal outcomes; the 
intervention was different from that of the review 
10. Coovadia (2007) 
 
The study had high risk of bias  
Sequence generation - NO 
Allocation concealment - NO 
Blinding - NO 
Intention to treat analysis - NO, available case analysis was done 
Loss of follow up - The study had 26 % loss to follow up 
Free of other sources of bias – YES 
11. Becquet (2009) The study outcomes were irrelevant for this review. The 
methodology was also irrelevant; it was a pooled data from 2 
cohort studies. 
 
Table 4.5 is a summary of 11 articles that were excluded from the review analysis.  These 
studies were eliminated due to various reasons as indicated in the table.  The independent 
reviewers (AP) and (OK) individually assessed the studies and (KH) was consulted for 
consensus regarding the decision to exclude Coovadia (2007). 
Stellenbosch University http://scholar.sun.ac.za
  52
4.3 RISK OF BIAS IN INCLUDED STUDIES 
Table 4.6: Risk of bias graph: review of authors' judgments about each risk of bias 
item presented as percentages across all included studies 
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Table 4.7: Risk of bias summary: review of authors' judgments about each risk of bias 
item for each included study   
 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
 
4.3.1 Randomisation 
Randomisation was confirmed in 2/3 articles; Thior (2006) and Nduati (2000), were 
considered low risk.  Peltier (2009), conducted a good quality interventional cohort study but 
since no method of randomisation was used, a judgement of high risk was given.   
 
4.3.2 Allocation (selection bias) 
Allocation concealment was confirmed in 2/3 articles; Thior (2006) and Nduati (2000).  A 
judgement of low risk was used.  Patients chose their interventional method in Peltier (2009), 
therefore, a judgement for high risk was used.   
 
 
Stellenbosch University http://scholar.sun.ac.za
  54
4.3.3 Blinding (performance bias and detection bias) 
Blinding was confirmed as low risk in 2/3 articles: Thior (2006) and Nduati (2000).  Despite 
study participants and researchers being unaware of the feeding options until 34 and 32 and 
weeks gestation, after that it was impossible to blind the participants. It is unclear whether 
the outcome assessors were blinded.  Therefore, a judgement of unclear of bias was used.  
In Peltier (2009), no blinding was done to both the participants and personnel, it was then 
considered unclear of whether outcome assessors were blinded or not.   
 
4.3.4 Incomplete outcome data (attrition bias) 
A judgement of low risk was confirmed in 3/3 articles included in the study. Intention to treat 
analysis was done in all the trials.  The participants were analysed according to the 
intervention they were allocated to regardless of whether they completed it or not.   
 
4.3.5 Selective reporting (reporting bias) 
According to Higgins and Green (2006:152), reporting bias entails a tendency to under-
report undesirable results or outcomes.  The reviewer did not identify any reporting bias in 
the included studies.  A judgement of low risk was confirmed in 3/3 articles included in the 
study for no risk of reporting bias.   
 
4.3.6 Other potential sources of bias 
Generally there were no other signs of any biases in all the 3 studies. A judgement of low 
risk was confirmed for ‘free of other sources of bias?’ (low risk).  ` 
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4.4 EFFECTS OF INTERVENTIONS 
4.4.1 HIV infection 
 
Study or Subgroup
Nduati 2000
Thior 2006
Peltier 2009
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 2 (P = 0.84); I² = 0%
Test for overall effect: Z = 3.51 (P = 0.0005)
Events
53
51
1
105
Total
197
588
227
1012
Events
32
32
0
64
Total
204
591
305
1100
Weight
53.7%
45.4%
0.8%
100.0%
M-H, Random, 95% CI
1.72 [1.16, 2.54]
1.60 [1.05, 2.46]
4.03 [0.16, 98.38]
1.67 [1.26, 2.23]
Experimental Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Exclusive Breastfeeding Formula feeding
 
Figure 4.1: Exclusive breastfeeding vs. Exclusive formula feeding as measured at 6, 7 
and 9 months of age. Outcome: HIV infection 
 
Figure 4.1 illustrates the HIV infection rate among the three studies included with a total of 
2112 infants.  The studies reported outcomes at 6, 7 and 9 months. In all the included 
studies, mothers exclusively breastfed for 6 months.  Exclusive breastfeeding was 
associated with a higher HIV transmission rate (RR 1.67, 95% CI, 1.26-2.23, p=0.0005).  
The probability of HIV infection in exclusive breastfeeding was 1.67 times higher than 
compared to the exclusive formula feeding arm.  The heterogeneity between the three 
studies was rated not important (Chi²= 0.35, p=0.84, I²=0%).  
 
Study or Subgroup
Nduati, 2000
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 3.45 (P = 0.0006)
Events
53
51
104
Total
197
588
785
Events
32
32
64
Total
204
591
795
Weight
54.2%
45.8%
100.0%
M-H, Random, 95% CI
1.72 [1.16, 2.54]
1.60 [1.05, 2.46]
1.66 [1.25, 2.22]
Exclusive breastfeeding Exclusive formula feeding Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF  
Figure 4.2: Sensitivity analysis: Exclusive breastfeeding for 6 months vs. Exclusive 
formula feeding as measured at 6 and 7 months of age. Outcome: HIV infection 
 
The results of sensitivity in figure 4.2 indicated no significant change when compared to the 
results of figure 4.2. Two studies by Nduati (2000) and Thior (2006), (n=1580) undeniably 
showed that exclusive breastfeeding is associated with a HIV infection rate (RR 1.66, 95% 
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CI, 1.25-2.22, p=0.0006). The heterogeneity between the three studies was rated as not 
important (Chi²= 0.05, p=0.82, I²=0 %).   
 
4.4.2 Infant mortality 
Study or Subgroup
Nduati 2000
Peltier 2009
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.30, df = 2 (P = 0.52); I² = 0%
Test for overall effect: Z = 3.06 (P = 0.002)
Events
17
7
28
52
Total
197
227
588
1012
Events
22
17
54
93
Total
204
305
591
1100
Weight
29.9%
14.5%
55.5%
100.0%
M-H, Random, 95% CI
0.80 [0.44, 1.46]
0.55 [0.23, 1.31]
0.52 [0.34, 0.81]
0.60 [0.43, 0.83]
Exclusive breastfeeding Formula feeding Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
 
Figure 4.3: Exclusive breastfeeding for 6 months vs. Exclusive formula feeding as 
measured at 6, 7 and 9 months of age. Outcome: Infant mortality 
 
The three trials included in the analysis provided dichotomous data on infant mortality. When 
the data was meta-analysed, it indicated that the outcomes favoured exclusive breastfeeding 
and are associated with a low mortality rate as compared to exclusive breastfeeding (RR 
0.60, 95% CI, 0.43-0.83, p=0.002).  Heterogeneity was not of concern in the study (Chi²= 
1.30, p=0.52, I²=0%).   
 
Study or Subgroup
Nduati, 2000
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 1.27, df = 1 (P = 0.26); I² = 21%
Test for overall effect: Z = 2.34 (P = 0.02)
Events
17
28
45
Total
197
588
785
Events
22
54
76
Total
204
591
795
Weight
38.2%
61.8%
100.0%
M-H, Random, 95% CI
0.80 [0.44, 1.46]
0.52 [0.34, 0.81]
0.61 [0.41, 0.92]
Exclusive breastfeeding Exclusive formula feeding Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF  
Figure 4.4: Sensitivity analysis: Exclusive breastfeeding for 6 months vs. Exclusive 
formula feeding as measured at 6 and 7 months of age. Outcome: Infant mortality 
 
Sensitivity analysis of two trials (n=1580) with outcomes measured at 6 and 7 months had 
statistically significant results of a 95% CI, 0.41- 0.92, p=0.02, RR 0. 61). Statistical 
heterogeneity (Chi²=1.27, p=0.26, I²=21%) was deemed unimportant.  This re-analysis did 
not materially change the results in figure 4.3, hence strengthening the confidence that can 
be placed in the results (Deeks et al., 2006:151).   
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4.4.3 HIV-free survival  
 
Study or Subgroup
Nduati, 2000
Peltier 2009
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 3.76, df = 2 (P = 0.15); I² = 47%
Test for overall effect: Z = 0.93 (P = 0.35)
Events
80
11
74
165
Total
197
227
588
1012
Events
58
18
73
149
Total
204
305
591
1100
Weight
44.9%
13.5%
41.6%
100.0%
M-H, Random, 95% CI
1.43 [1.08, 1.88]
0.82 [0.40, 1.70]
1.02 [0.75, 1.38]
1.15 [0.86, 1.55]
Experimental Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF
 
Figure 4.5: Exclusive breastfeeding for 6 months vs. Exclusive formula feeding as 
measured at 7, 9 and 24 months of age. Outcome: HIV-free survival 
 
A pooled analysis of three trials (n=2112) provided dichotomous data on HIV-free survival. 
There was a non-significant tendency towards longer HIV-free survival in the exclusive 
formula feeding group in comparison to exclusive breastfeeding (RR 1.15, 95% CI, 0.86-
1.55, p=0.35). The level of statistical heterogeneity was considered moderate (Chi²=3.76, 
p=0.15, I²=47%).   
 
 
Study or Subgroup
Nduati, 2000
Peltier 2009
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 3.15, df = 2 (P = 0.21); I² = 36%
Test for overall effect: Z = 1.30 (P = 0.19)
Events
80
11
86
177
Total
197
227
588
1012
Events
58
18
80
156
Total
204
305
591
1100
Weight
45.0%
11.1%
43.9%
100.0%
M-H, Random, 95% CI
1.43 [1.08, 1.88]
0.82 [0.40, 1.70]
1.08 [0.81, 1.43]
1.19 [0.92, 1.54]
Experimental Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF  
Figure 4.6: Overall sensitivity analysis: Exclusive breastfeeding for 6 months vs. 
Exclusive formula feeding as measured at 9, 18 and 24 months. Outcome: HIV-free 
survival 
 
Sensitivity analysis was performed on the same three trials (n=2112) with outcomes 
measured at different intervals to those of figure 4.8. The results still indicated that exclusive 
formula feeding did not significantly change the duration of HIV-free survival (RR 1.19, 95% 
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CI, 0.92-1.54, p=0.19).  The heterogeneity between the three studies was rated not 
important (Chi²= 3.15, p=0.21, I²=36 %).   
 
Study or Subgroup
Nduati, 2000
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 1.95, df = 1 (P = 0.16); I² = 49%
Test for overall effect: Z = 1.56 (P = 0.12)
Events
80
86
166
Total
197
588
785
Events
58
80
138
Total
204
591
795
Weight
50.6%
49.4%
100.0%
M-H, Random, 95% CI
1.43 [1.08, 1.88]
1.08 [0.81, 1.43]
1.24 [0.94, 1.64]
Experimental Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF
 
Figure 4.7: Sensitivity analysis: exclusive breastfeeding for 6 months vs. Exclusive 
formula feeding as measured at 18 and 24 months. Outcome: HIV-free survival 
 
A second sensitivity analysis was done on two trials (n=1580) with dichotomous data on 
HIV-free survival measured at 18 and 24 months. The results still had a non-significant 
tendency towards a longer HIV-free survival in the exclusive formula feeding (RR 1.24, 95% 
CI, 0.94-1.64, p=0.12). The level of statistical heterogeneity was moderate (Chi²=1.95, 
p=0.16, I²=49%).   
 
Study or Subgroup
Peltier 2009
Thior 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.29, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.09 (P = 0.93)
Events
11
74
85
Total
227
588
815
Events
18
73
91
Total
305
591
896
Weight
14.6%
85.4%
100.0%
M-H, Random, 95% CI
0.82 [0.40, 1.70]
1.02 [0.75, 1.38]
0.99 [0.75, 1.31]
Experimental Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours EBF Favours EFF  
Figure 4.8: Sensitivity analysis exclusive breastfeeding for 6 months vs. Exclusive 
formula feeding as measured at 7 and 9 months. Outcome: HIV-free survival 
 
The last sensitivity analysis on two trials (n=1711) measuring HIV-free survival at 7 and 9 
months showed no evidence of a difference in outcomes between the two groups at 6 and 7 
months (RR 0.99, 95% CI, 0.75-1.31, p=0.93).  Statistical heterogeneity was confirmed 
unimportant (Chi²=0.29, p=0.59, I²=0%).   
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4.5 CONCLUSION  
Chapter 4 focused on the analysis of the data.  The results indicated that exclusive 
breastfeeding is associated with HIV infection from mother to child as compared to exclusive 
formula feeding but this intervention is associated with high mortality rate.  The result 
showed no statistically differences in HIV free survival between the two interventions.   
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CHAPTER 5 
DISCUSSION 
 
5.1 INTRODUCTION 
This section provides a discussion of the results in chapter 4 to provide meaningful 
explanations to the data analysed in relation to the objectives of the review.  The study’s 
main objective was to evaluate the evidence on exclusive breastfeeding versus formula 
feeding and/ or mixed feeding with the use of antiretroviral prophylaxis in the prevention of 
HIV-1 transmission from mother to child.  It then, finally either accepts or rejects the 
hypothesis: exclusive breastfeeding is effective in the prevention of HIV-1 transmission from 
mother to child.   
 
5.2 DISCUSSION 
5.2.1 HIV infection 
The review found that the rate of HIV infection is higher in exclusive breastfeeding when 
compared to formula feeding (RR 1.26, 95%CI, 1.26-2.23, p=0.0005).  The studies included 
in the analysis reported a good compliance rate in both feeding methods which have been 
found to have a significant impact on the transmission rate (Chapter 2: 2.2- 2.3).  Sensitivity 
analysis was incorporated due to the fact that HIV infection was measured at different 
intervals across studies. It confirmed the results that exclusive breastfeeding was associated 
with higher HIV infection rates as compared to exclusive formula feeding.  There was no 
evidence of statistical heterogeneity.  Recently, a systematic review of six trials on 
interventions for preventing late postnatal mother-to-child transmission of HIV concluded that 
complete avoidance of breastfeeding is efficacious in preventing MTCT of HIV (Horvath et 
al., 2010:2).  In addition, if breastfeeding is initiated, a combination of two interventions is 
essential, that is exclusive breastfeeding during the first few months of life and extended 
antiretroviral prophylaxis (Horvath et al., 2010:2).  The included studies had participants’ 
breastfeeding exclusively for six months with HIV prophylaxis for infants or maternal HAART 
of which none was extended.  None of the included studies compared exclusive 
breastfeeding with mixed feeding.  An interventional cohort study conducted in Durban, 
South Africa found that infants who were mixed fed had significantly high rates of acquisition 
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of MTCT of HIV and were 11 times at risk (HR (hazard ratio) 10.87, 95% CI 1.51-78.00, 
p=0.018) (Coovadia et al., 2007:1107).   
In some studies, exclusive breastfeeding has been associated with a lower risk of postnatal 
transmission of HIV as compared to non-exclusive breastfeeding, that is, breastfeeding with 
formula, other fluids (water, fruit juice) or solids (baby food) (Leroy 2001:15; Iliff et al., 
2005:699). The introduction of solid foods or animal milk to breastfeeding infants born to HIV 
positive mothers before the age of 3 months was associated with a fourfold greater risk of 
postnatal transmission at 6 months compared with exclusive breastfeeding (Iliff et al., 
2005:703).  The overall result of this review and that which Horvath (2010) favours is 
complete avoidance of breastfeeding. 
 
5.2.2 Infant mortality 
The results of this meta-analysis indicated that exclusive breastfeeding  is associated with a 
lower infant mortality rate as compared to exclusive formula feeding (RR 0.60, 95% CI, 0.43-
0.83, p=0.002 , sensitivity analysis on outcome measured between 6 and 7 months, 95% CI, 
0.41- 0.92, p=0.02, RR 0.61). There was no evidence of statistical heterogeneity in the 
results (Chi²=1.30, p=0.52, I²=0%) and (Chi²=1.27, p=0.26, I²=21%). Each of the included 
studies individually reported lower infant mortality rates as compared to exclusive formula 
feeding. Horvath et al., (2010:2) supported this finding stating/saying that despite exclusive 
formula feeding being efficacious in preventing  MTCT of HIV, it is associated with mortality 
(e.g., diarrhoeal morbidity if formula is prepared without clean water).  Coovadia et al., 
(2007:1107) had the same findings; the study showed that mortality rate is lower in exclusive 
breastfed infants as compared to exclusively formula fed infants. The cumulative 3 month 
mortality in exclusively breastfed infants was 6.1% versus 15.1% in infants given 
replacement feeds.   
 
5.2.3 HIV-free survival 
The review found that exclusive breastfeeding is not associated with longer HIV-free 
survival, when outcomes were measured at 7, 9 and 24 months (RR 1.15, 95% CI, 0.86-
1.55, p=0.35). The sensitivity analysis was performed on the same three trials (n=2112) with 
outcomes measured at 9, 18 and 24 months. The results still indicated that exclusive 
breastfeeding was not associated with an increase in HIV-free survival (RR 1.19, 95% CI, 
0.92-1.54, p=0.19).  Even if there was heterogeneity between the three studies, it was rated 
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as not important (Chi²= 3.15, p=0.21, I²=36 %).  The performed sensitivity analyses where 
outcomes were measured at 18 and 24 months (Nduati, 2000; Thior, 2006) or at 7 and 9 
months (Peltier, 2009; Thior, 2006) did not yield any different findings.   
Two individual studies Peltier (2009) and Thior (2006), that were included in the meta-
analysis reported the same findings as in this review, while Nduati (2000), reported a 
significant lower HIV-free survival in the breastfeeding arm.  According to the review, 
exclusive breastfeeding is not associated with a longer HIV-free survival.   
 
5.3 OVERALL COMPLETENESS AND APPLICABILITY OF EVIDENCE 
The following research question was used as a guide before initiation of the review: Is 
exclusive breastfeeding effective in the prevention of HIV-1 transmission of Mother to Child?  
The reviewer conducted an extensive literature search to identify all literature and studies 
related to the review.   
The included studies contributed and addressed exclusive breastfeeding and its 
effectiveness in the prevention of HIV-1 transmission from Mother to Child. They compared 
exclusive breastfeeding to exclusive formula feeding.  None of the studies compared 
exclusive formula feeding with mixed feeding.  In daily practice, mixed feeding is 
discouraged due to its association with high transmission rate of HIV-1.  It would be 
unethical for trialists to randomly assign patients to mixed feeding. Though some patients did 
not completely adhere and comply with either exclusive breastfeeding or formula feeding, 
the investigators did not report the results as mixed feeding.  Exclusive formula feeding is 
associated with a 0% HIV-1 transmission rate.  Therefore, this might disturb the 
completeness of the evidence.   
Despite this, HIV infection, infant mortality and HIV-free survival were addressed. The 
studies were conducted in developing countries in semi-rural and in cities. These multi-
centred results increase the generalisability.  They can be applied in a number of settings, 
that is, the evidence can be transferred to different areas.   
In some developing countries, especially Botswana and South Africa, the government 
provides free formula feeding to infants. These mothers need intensive training on how to 
make the feeding option safe (clean preparation) since it is associated with high mortality 
from infections such as diarrhoea, respiratory and ear infections.  A mother who chooses to 
breastfeed must be encouraged to do it exclusively during the first 4-6 months.  One of the 
excluded studies, Coovadia et al., (2007), conducted a study in South Africa. It was found 
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that mixed feeding was associated with high HIV- transmission as compared to the other 
feeding options.  Evidence on HIV-free survival could not show any promise that exclusive 
breastfeeding could be associated with a longer HIV-free survival period.   
 
5.4 QUALITY OF EVIDENCE 
The review consists of two randomised and one cohort study.  The RCTs are mostly of good 
quality.  Randomised controlled studies are considered as the best designs in addressing 
research questions regarding effectiveness of therapeutic interventions (Higgins & Green, 
2006:60).  They are characterised by selection criteria, random sampling, control, blinding 
procedures, intervention protocol, intention to treat, effect size and sometimes crossover 
designs (Brink et al., 2008:96).  These characteristics decrease the risk of bias in studies.  
All the included studies had a control group (exclusive formula feeding).  The control group 
was used as a comparison to observe and evaluate the effects of exclusive breastfeeding.   
Cohort studies can be included in systematic reviews.  Peltier (2009), did not randomly 
assign subjects to an intervention; the participants chose their feeding options.  This is 
important as sometimes participants fail to adhere and comply with the randomly assigned 
infant feeding option, due to socio-economic barriers. Peltier (2009), reported a lower rate of 
HIV-1 transmission from mother to child measured at 9 months (1 infant in exclusive 
breastfeeding and none in exclusive formula feeding) as compared to other studies.   
In this review a methodological quality assessment tool ‘risk of bias table’ was used to 
assess studies individually for quality. The two randomised controlled studies had allocation 
concealment, however, blinding was unclear in both. The three studies reported attrition bias 
between 3.4%-17%.  Intention to treat analysis was confirmed in 3/3 articles.  None of the 
included studies had evidence of selective (reporting) bias.  Other sources of bias were not 
found in any of the articles. 
 
5.5 POTENTIAL BIASES IN THE REVIEW PROCESS 
During the review process, measures were taken to minimise the risk of bias.  The same 
research question was used as a guide and it remained consistent throughout. The reviewer 
was cautious not to modify it.   
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An extensive literature search was conducted across a wide range of databases. The main 
purpose was to retrieve as many articles as possible and to avoid excluding important 
studies, thus eliminating selection bias. 
Quality assessment was performed using standardised data extraction tools from the 
Cochrane collaboration.  Two independent reviewers, (AP) and (OK) independently 
assessed the methodological quality. They determined which study met the inclusion criteria. 
Disagreements were solved by discussion, a third reviewer (KH) was contacted for further 
consultations. Prof. Hofmeyr, an expert in systematic reviews and editor of Cochrane 
collaboration group for systematic reviews, was contacted repeatedly during quality 
assessments.  The risk of bias was minimised by following these procedures.   
 
5.6 AGREEMENTS AND DISAGREEMENTS WITH OTHER STUDIES  
Generally, the results of the review do not vary from what other reviewers have found.  A 
systematic review by Horvath et al., (2010) concluded that complete avoidance of 
breastfeeding is efficacious in preventing MTCT, but it is associated with significant higher 
infant mortality.  Exclusive breastfeeding with extended antiretroviral prophylaxis can 
minimise the chances of MTCT.  The review did not focus on breastfeeding and extended 
antiretroviral prophylaxis.  Some excluded studies on standard antiretroviral versus extended 
antiretroviral prophylaxis and exclusive breastfeeding reported lower MTCT in the extended 
antiretroviral arm (Bedri, 2008; Dabis, 1999; Kumwenda, 2008;, Lehman, 2008; Kilewo, 
2008; Guay, 1999; Violari, 2008; and Homsy, 2010).   
Two of the included studies individually reported the same finding as in this review, while 
one reported a lower HIV-free survival among exclusive breast-fed infants.  
 
5.7 CONCLUSIONS ON THE TWO INTERVENTIONS 
5.7.1 Exclusive breastfeeding 
The results of the review have shown the risks and benefits of exclusive breastfeeding.  The 
trialists of the included studies reported less than 100% compliance or adherence to 
exclusive breastfeeding by study participants, respectively.  The results showed a significant 
higher HIV transmission in the breast-fed infants, and they did not show any evidence that 
exclusive breastfeeding could be associated with a longer HIV-free survival as reported by 
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the individual studies.  According to the findings, mortality is reduced through exclusive 
breastfeeding.   
 
5.7.2 Exclusive Formula feeding 
According to the literature, exclusive formula feeding carries a 0% rate of HIV transmission.  
The findings of the review indicated a significant benefit of choosing EFF as an infant 
feeding option for the prevention of HIV-1 transmission. However, in included studies, HIV 
infection rates under exclusive formula feeding were reported, this could be an indicator of 
mixed feeding and poor adherence.  EFF is also a major risk factor of mortality in infants.   
 
5.8 RECOMMENDATIONS 
5.8.1 Excusive breastfeeding 
There is a need for larger prospective, multi-centred RCTs of good methodological quality on 
exclusive breastfeeding to obtain more evidence based results.  Health care workers and 
policy makers play a major role in the welfare of the population.  It is critical that if the 
AFASS criterion of EFF is not met, exclusive breastfeeding should be encouraged. Some 
mothers opt for breastfeeding as a personal choice and this shouldn’t hinder the health care 
workers from supporting and encouraging them to adhere completely to this feeding option.  
The use of antiretroviral prophylaxis as prescribed should also be emphasized.  This has 
shown to lessen the chances of MTCT.  Studies have also shown that extended antiretroviral 
therapy decreases MTCT of HIV.  Currently, the national regime of antiretroviral therapy in 
breastfeeding is not extended, policy makers could review this and consider if it is not 
feasible in the current state.   
There are several challenges regarding the promotion of exclusive breastfeeding especially 
in HIV positive mothers.  Socio-cultural barriers play a major role.  Health care workers and 
public health policy makers can aim at attending everyone at a community level.  Several 
programmes such as the South African-based non government organisation; Mothers to 
Mothers and community breastfeeding counsellors should be expanded and aim at doing 
home visits, organising health education workshops at community level.  Home or family 
visits may also help individual family members to get more clarity and understanding.  These 
programmes should encourage the entire community, convince them to involve themselves 
in issues regarding HIV and breastfeeding especially before large scaled studies can be 
done because these factors hinder research and daily evidence based practice.   
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HIV activists’ programmes aims at supporting those infected and affected using personal 
experience.  There is a need in the community to have such people especially those who 
opted for exclusive breastfeeding with an HIV positive status.  Such people may bring hope, 
encouragement and support to these HIV positive mothers.  The health care workers should 
assist in facilitation of these programmes to make them feasible.   
5.8.2 Exclusive formula feeding 
An exclusive formula feeding option has shown promise on the effectiveness of preventing 
HIV-1 transmission from mother to child.  However, it is associated with higher infant 
mortality.  Literature has shown that EFF can be considered in circumstances where it is 
sustainable, safe, affordable, accessible and feasible.  The government policies need to be 
reinforced to improve socio-economic conditions of the people.  Due to poor housing, water, 
sanitation, access to health facilities in a large number of HIV populations, the AFASS 
criteria cannot be met.  Therefore there is a need in such situations to promote excusive 
breastfeeding and antiretroviral adherence thus discouraging exclusive formula feeding.  
However, if AFASS criterion is met, health care providers and decision makers need to 
promote EFF and educate how to prepare, store and to give formula milk in a safe way.  
Community and individual family involvement is necessary to overcome socio-cultural 
barriers.   
In all instances, mixed feeding should be discouraged due to its risks of high HIV 
transmission and mortality rates.  Large multicentre RCTs of appropriate methodological 
quality on a safe feeding option in the prevention of MTCT transmission HIV-1 should be 
conducted to provide more evidence. 
 
5.9 CONCLUSION 
Infant feeding choices in HIV exposed infants have become a tremendous challenge 
especially in the developing countries.  The population is not well informed due to illiteracy 
and there is poor access to basic health services.  Mostly, cultural backgrounds play a major 
role in decision making regarding safe infant feeding guidelines and unfortunately this affects 
the well-being of the infants. The reviewer discussed, concluded the research findings and 
made suggestions based on the results.  These results inform practice and ideas were given 
on how to expand the existing body of knowledge such as the conducting of multi-centred, 
RCTS of appropriate methodological quality.   
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ANNEXURES 
 
ANNEXURE I. – Data extraction forms  
Data extraction form; Nduati, 2000. 
1.  Source 
Study ID 01 
Reviewer Angel Phuti; Oswell Khondowe 
Author & year Nduati, R., John, G., Mbori-Ngacha, D., Richardson, B., 
Overbaugh, J., Mwatha, A., Ndinya-Achola, J., Bwayo, J., 
Onyango, F. E., Hughes, J. & Kreiss, J.   
Journal 2000: JAMA, 283, 1167-74. 
Title Effect of Breastfeeding and formula on transmission of HIV-1: A 
randomised Clinical trial. 
Country Nairobi-Kenya 
 
 
2. Eligibility criteria 
(Indicate with a cross the appropriate one) 
2.1 Types of studies 
Randomised Controlled Trial X 
Quasi-experimental  
Cohort study  
Published data X 
Unclear/NO  
 
2.2 Types of participants 
HIV exposed babies born from HIV-1 positive 
mothers. 
X 
Unclear/NO  
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2.3 Types of interventions  
Exclusive Breastfeeding vs. Formula feeding 
under a certain antiretroviral  
X 
Exclusive breastfeeding vs. Mixed feeding 
under a certain antiretroviral. 
 
Unclear/NO.  
 
2.4 Types of outcomes 
HIV infection X 
Infant mortality X 
HIV free survival X 
Unclear/NO  
 
If any of the above answers are ‘NO’, do not proceed. If study is to be included in ‘Excluded 
studies’ of the review, record the information into ‘the table of excluded studies’.   
 
2.6 Lost to follow up <20% 
Equation YES   X NO 
 
2.6.1 Reasons for loss to follow up 
Reasons for attrition included: maternal death, loss to follow up/ not returning to study site.  
 
 
 
 
2.6.2 Other reasons for exclusion 
None 
 
 
 
 
 
3. Methodology 
3.1 Study design 
RCT X 
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Quasi-experimental  
Cohort  
 
3.2 Study duration 
Month & Year November 1992 – July 1998 
 
3.3 Eligibility criteria 
Participant: HIV exposed infants whose mothers who are HIV-1 positive 
Intervention: Exclusive breastfeeding (with antiretroviral) 
Comparison: Exclusive formula feeding 
Outcomes: HIV infection, mortality 
Measured at 6,18 & 24 months 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool: Methodological quality/ Risk of bias 
assessment.  Each question or domain should be answered with either; ‘LOW RISK’ or 
‘HIGH RISK’ or ‘UNCLEAR’. 
DOMAIN/QUESTION JUDGEMENT DESCRIPTION 
Sequence generation? Low risk Randomisation method was 
used. 
Allocation concealment? Low risk Computer generation 
Blinding of participants, 
personnel and outcome 
assessor? 
Low risk and Unclear for 
outcome assessors 
At 32 weeks until delivery the 
participants were unblinded 
after that, it was impossible 
to blind. 
Incomplete outcome data 
adequately addressed? 
Low risk Intention to treat analysis 
was done.   
 Study free of selective 
outcome reporting? 
Low risk - 
Free of other bias? Low risk - 
 
3.5 Participants 
Sample size 425 mothers who gave birth to 401  infants 
Total number included in the analysis 401 
Age during initiation of intervention Immediately after delivery 
Sex Female and male 
Diagnostic criteria for HIV Enzyme linked Immuno-absorbent assay 
Setting Nairobi; Kenya 
Socio-demographic Low socio economic status 
Country Kenya 
Date of study November 1992- July 1998 
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3.6 Interventions 
Experimental group with or without antiretroviral 
Type Duration 
EBF 6 months 
Control group with or without antiretroviral  
Type Duration 
EFF 6 
 
3.7 Outcome measures as stated in the review 
(Tick appropriate box) 
1. HIV infection YES    X NO 
2. Infant mortality YES    X NO 
3.  HIV free survival YES    X NO 
 
3.8 Outcomes definitions 
1. HIV infection:                HIV positive through the use of ELISA test 
2. Infant mortality:            Death 
3.  HIV free survival:         HIV infection and death 
 
 
4. Results 
Number of Patients: 
 Randomised or allocation Analysed 
Experimental 197 197 
Control 204 204 
Total 401 401(The total number that 
remained after delivery) 
 
4.1 Summary data for each intervention group (at 6 months) 
1. HIV infection Event No event Total 
Experimental group 53 159 197 
Control group 32 181 204 
  
Stellenbosch University http://scholar.sun.ac.za
  79
(Measured at 6 months) 
2. Infant mortality Event No event Total 
Experimental group 17 180 187 
Control group 22 182 204 
  
 
(Measured at 24 months) 
3.HIV free survival Event No event Total 
Experimental group 80 117 197 
Control group 58 146 204 
  
4.2 Continuous data 
Outcome Experimental 
group 
(mean±SD) 
Control 
group 
(mean±SD) 
WMD CI 95% P- value 
      
      
      
 
4.3 Estimate of effect with confidence interval/ P-value 
1. HIV infection RR CI 95% P-value 
Experimental group    
Control group    
 
1. Infant mortality RR CI 95% P-value 
Experimental group    
Control group    
 
1. HIV free survival RR CI 95% P-value 
Experimental group    
Control group    
 
4.4 Subgroup analysis 
Outcomes measured at different age (month) 
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4.5 Miscellaneous 
Key conclusions The frequency of HIV-1 was 16.2% in this 
randomised clinical trial, and the majority of 
infections occurred during breastfeeding.  
The use of breastmilk substitutes prevented 
44% of infant infections and was associated 
with improved HIV- free survival.    
Other significant comments from authors - 
References to other relevant trials X 
More information required - 
Others:  
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Data extraction form; Thior, 2006. 
1.  Source 
Study ID 02 
Reviewer Angel Phuti and Oswell Khondowe 
Author & year Thior, I., Lockman, S., Smeaton, L. M., 
Shapiro, R. L., Wester, C., Heymann, S. J., 
Gilbert, P. B., Stevens, L., Peter, T., Kim, S., 
Van Widenfelt, E., Moffat, C., Ndase, P., 
Arimi, P., Kebaabetswe, P., Mazonde, P., 
Makhema, J., Mcintosh, K., Novitsky, V., 
Lee, T. H., Marlink, R., Lagakos, S. & Essex, 
M.  2006 
Journal JAMA, 296, 794-805.   
Title Breastfeeding plus infant zidovudine 
prophylaxis for 6 months vs formula feeding 
plus infant zidovudine for 1 month to reduce 
mother-to-child HIV transmission in 
Botswana: a randomized trial: the Mashi 
Study.   
Country Botswana 
 
 
2. Eligibility criteria 
(Indicate with a cross the appropriate one) 
2.1 Types of studies 
Randomised Controlled Trial X 
Quasi-experimental  
Cohort study  
Published data X 
Unclear/NO  
 
2.2 Types of participants 
HIV exposed babies born from HIV positive 
mothers. 
X 
Unclear/NO  
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2.3 Types of interventions  
Exclusive Breastfeeding vs. Formula feeding 
under a certain antiretroviral or not.  
X 
Exclusive breastfeeding vs. Mixed feeding 
under a certain antiretroviral or not. 
 
Unclear/NO.  
 
2.4 Types of outcomes 
HIV infection X 
Infant mortality X 
HIV free survival X 
Unclear/NO  
 
If any of the above answers are ‘NO’, do not proceed. If study is to be included in ‘Excluded 
studies’ of the review, record the information into ‘the table of excluded studies’.   
 
2.6 Lost to follow up <20% 
Equation YES   X NO 
 
2.6.1 Reasons for loss to follow up 
Attrition rate included: Loss to follow up and failure to complete HIV tests 
 
 
 
 
2.6.2 Other reasons for exclusion 
 
 
 
 
 
 
3. Methodology 
3.1 Study design 
RCT X 
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Quasi-experimental  
Cohort  
 
3.2 Study duration 
Month & Year August 2006 
 
3.3 Eligibility criteria 
Participants: HIV exposed infants whose mothers who are HIV-1 positive 
Interventions: Exclusive breastfeeding under an antiretroviral 
Comparisons: Exclusive formula feeding 
Outcomes: HIV infection, Infant mortality, HIV free survival 
 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool: Methodological quality/ Risk of bias 
assessment.  Each question or domain should be answered with either; ‘LOW RISK’ or 
‘HIGH RISK’ or ‘UNCLEAR’. 
DOMAIN/QUESTION JUDGEMENT DESCRIPTION 
Sequence generation? Low risk Randomisation 
Allocation concealment? Low risk Centralised controlled trial 
Blinding of participants, 
personnel and outcome 
assessor? 
Low risk and unclear for 
outcome assessors 
Blinding was done from 34 
weeks until delivery, after 
that it was impossible to blind 
participants.  It is unclear 
whether outcome assessors 
were blinded or not. 
Incomplete outcome data 
adequately addressed? 
Low risk Intention to treat analysis 
was done 
 Study free of selective 
outcome reporting? 
Low risk No evidence of reporting of 
desirable results only. 
Free of other bias? Low risk - 
 
3.5 Participants 
Sample size 1200 mothers who gave birth to 1179 infants 
who could be in the study initially. 
Total number included in the analysis 1179 
Age during initiation of intervention From birth  
Sex Male and female 
Diagnostic criteria for HIV Polymerase chain reaction and Enzyme 
Linked Immuno-sorbent Assay. 
Setting 1 city, 1 town and 2 large villages. 
Socio-demographic Low socio economic status 
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Country Botswana 
Date of study 27 March 2001- 29 October 2003 
 
3.6 Interventions 
Experimental group with or without antiretroviral 
Type Duration 
EBF 6 months 
Control group with or without antiretroviral  
Type Duration 
EFF 6 months 
3.7 Outcome measures as stated in the review 
(Mark appropriate box) 
1. HIV infection YES   X NO 
2. Infant mortality YES   X NO 
3.  HIV free survival YES   X NO 
 
3.8 Outcomes definitions 
1. HIV infection: Infants with PCR retested on separate sample or by ELISA at 18 months. 
Time of infection based on the date of the earliest positive result test. 
2. Infant mortality: Death 
3.  HIV free survival: Death or infection by HIV 
 
 
4. Results 
Number of Patients: 
 Randomised or allocation Analysed 
Experimental 588 588 
Control 591 591 
Total 1179 1179 
 
4.1 Summary data for each intervention group 
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Measured at 7 months 
1. HIV infection Event No event Total 
Experimental group 51 537 588 
Control group 32 559 591 
  
Measured at 18 months 
1. HIV infection Event No event Total 
Experimental group 53 535 588 
Control group 33 558 591 
 
 
 
 
Measured at 7 months 
2. Infant mortality Event No event Total 
Experimental group 28 560 588 
Control group 54 537 591 
  
 
Measured at 18 months 
2. Infant mortality Event No event Total 
Experimental group 48 540 588 
Control group 62 529 591 
 
Measured at 7 months 
3. HIV free survival Event No event Total 
Experimental group 74 514 588 
Control group 73 518 591 
  
Measured at 18 months 
3. HIV free survival Event No event Total 
Experimental group 86 502 588 
Control group 80 511 591 
 
Stellenbosch University http://scholar.sun.ac.za
  86
4.2 Continuous data 
Outcome Experimental 
group 
(mean±SD) 
Control 
group 
(mean±SD) 
WMD CI 95% P- value 
      
      
      
 
4.3 Estimate of effect with confidence interval/ P-value 
1. HIV infection RR CI 95% P-value 
Experimental group    
Control group    
 
1. Infant mortality RR CI 95% P-value 
Experimental group    
Control group    
 
 
1. HIV free survival RR CI 95% P-value 
Experimental group    
Control group    
 
 
4.4 Subgroup analysis 
Outcomes were measured at different age months; 7 and 18 months. 
 
 
 
 
 
4.5 Miscellaneous 
Key conclusions Breastfeeding with zidovudine prophylaxis 
was not as effective as formula feeding in 
preventing postnatal  HIV transmission, but 
was associated with a lower mortality at 7 
months. Both strategies had comparable HIV 
free survival at 18 months. 
Other significant comments from authors The results demonstrate the risk of formula 
feeding to infants in Sub Saharan Africa, and 
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the need for studies of alternative strategies. 
References to other relevant trials YES 
More information required - 
Others: - 
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Data extraction form; Peltier, 2009. 
1.  Source 
Study ID 03 
Reviewer Angel Phuti and Oswell Khondowe 
Author & year Peltier, C. A., Ndayisaba, G. F., Lepage, P., Van Griensven, J., 
Leroy, V., Pharm, C. O., Ndimubanzi, P. C., Courteille, O. & Arendt, 
V.  2009 
Journal . AIDS, 23, 2415-23.   
Title Breastfeeding with maternal antiretroviral therapy or formula feeding 
to prevent HIV postnatal mother-to-child transmission in Rwanda.  
AIDS, 23, 2415-23.   
 
Country Rwanda 
 
 
2. Eligibility criteria 
(Indicate with a cross the appropriate one) 
2.1 Types of studies 
Randomised Controlled Trial  
Quasi-experimental  
Cohort study X 
Published data X 
Unclear/NO  
 
2.2 Types of participants 
HIV exposed babies born from HIV-1 positive 
mothers. 
X 
Unclear/NO  
 
2.3 Types of interventions  
Exclusive Breastfeeding vs. Formula feeding 
under a certain antiretroviral or not.  
X 
Exclusive breastfeeding vs. Mixed feeding 
under a certain antiretroviral or not. 
 
Unclear/NO.  
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2.4 Types of outcomes 
HIV infection X 
Infant mortality X 
HIV free survival X 
Unclear/NO  
 
If any of the above answers are ‘NO’, do not proceed. If study is to be included in ‘Excluded 
studies’ of the review, record the information into ‘the table of excluded studies’.   
 
2.6 Lost to follow up <20% 
Equation YES   X NO 
 
2.6.1 Reasons for loss to follow up 
Reasons for attrition rate included: death and loss to follow up. 
 
 
 
 
2.6.2 Other reasons for exclusion 
 
 
 
 
 
 
3. Methodology 
3.1 Study design 
RCT  
Quasi-experimental  
Cohort X 
 
 
3.2 Study duration 
Month & Year May 2005-January 2007 
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3.3 Eligibility criteria 
Participants: HIV exposed infants whose mothers who are HIV-1 positive 
Interventions: Exclusive breastfeeding under an antiretroviral 
Comparisons: Exclusive formula feeding 
Outcomes: HIV infection, Infant mortality, HIV free survival 
 
 
3.4 Cochrane Collaboration ‘Risk of Bias’ Tool: Methodological quality/ Risk of bias 
assessment.  Each question or domain should be answered with either; ‘LOW RISK’ or 
‘HIGH RISK’ or ‘UNCLEAR’. 
DOMAIN/QUESTION JUDGEMENT DESCRIPTION 
Sequence generation? High risk Non randomised cohort 
study 
Allocation concealment? High risk - 
Blinding of participants, 
personnel and outcome 
assessor? 
High risk No blinding done 
Incomplete outcome data 
adequately addressed? 
Low risk Intention to treat analysis 
was done 
 Study free of selective 
outcome reporting? 
Low risk No evidence of reporting of 
desirable results only. 
Free of other bias? Low risk - 
 
 
3.5 Participants 
Sample size 532 
Total number included in the analysis 532 
Age during initiation of intervention From birth  
Sex Male and female 
Diagnostic criteria for HIV HIV DNA PCR test 
Setting Government run facilities: 1 rural, 2 semi 
rural and 2 urban. 
Socio-demographic Low socio economic status- 
Country Rwanda 
Date of study May 2005- January 2007 
 
3.6 Interventions 
Experimental group with or without antiretroviral 
Type Duration 
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EBF 6 months 
Control group with or without antiretroviral  
Type Duration 
EFF 6 months 
 
3.7 Outcome measures as stated in the review 
(Mark appropriate box) 
1. HIV infection YES   X NO 
2. Infant mortality YES   X NO 
3.  HIV free survival YES   X NO 
 
3.8 Outcomes definitions 
1. HIV infection: positive result test of HIV DNA PCR tested at 6,weeks, 3 months, 7 and 9 
months of age. 
2. Infant mortality:  
3.  HIV free survival: Death or infection by HIV 
 
 
4. Results 
Number of Patients: 
 Randomised or allocation Analysed 
Experimental 227 227 
Control 305 305 
Total 532 532 
 
 
4.1 Summary data for each intervention group 
Measured at 9 months 
1. HIV infection Event No event Total 
Experimental group 1 226 227 
Control group 0 305 305 
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Measured at 9 months 
2. Infant mortality Event No event Total 
Experimental group 7 220 227 
Control group 17 228 308 
 
Measured at 9 months 
3. HIV free survival Event No event Total 
Experimental group 11 216 227 
Control group 18 287 305 
  
4.2 Continuous data 
Outcome Experimental 
group 
(mean±SD) 
Control 
group 
(mean±SD) 
WMD CI 95% P- value 
      
      
      
 
4.3 Estimate of effect with confidence interval/ P-value 
1. HIV infection RR CI 95% P-value 
Experimental group    
Control group    
 
1. Infant mortality RR CI 95% P-value 
Experimental group    
Control group    
 
1. HIV free survival RR CI 95% P-value 
Experimental group    
Control group    
 
4.4 Subgroup analysis 
Outcomes measured at different intervals. 
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4.5 Miscellaneous 
Key conclusions Maternal HAART while breastfeeding could 
be a promising alternative strategy in 
resource- limited countries.   
Other significant comments from authors  
References to other relevant trials YES 
More information required - 
Others: - 
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ANNEXURE III.-prisma 2009 checklist 
Section/topic  # Checklist item  
Repor
ted on 
page 
#  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
I 
ABSTRACT  
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
Iii 
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
1-4 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4-6 
METHODS  
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
10,39 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow‐up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving 
rationale.  
5-6 
28-31 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
7, 28-
29 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
29-30 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta‐analysis).  
30-31 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
7-8 
Appen
dix 
1:72-89
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
7, 30-
31 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
8, 51-
53 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
35 
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Synthesis of 
results  
14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I2) 
for each meta‐analysis.  
45-46 
 
 
Section/topic  # Checklist item  
Repor
ted on 
page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
32-36 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre‐specified.  
36-38 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
42 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
44,46,4
8 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
45,47,4
9, 51-
53 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a 
forest plot.  
45,46,4
8, 54-
57 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
54-58 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 
(see Item 15).  
45,47,4
9, 51-
53 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
54-57 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
59-60 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
61-63 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
64 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
No 
funding 
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ANNEXURE IV - Editor’s declaration 
 
(See next page, declaration could not fit due to technical issues). 
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